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A B S T R A C T
Background
Policy makers, health staff and communities recognise that health services in lower- and middle-income countries need to improve
people’s access to HIV treatment and retention to treatment programmes. One strategy is to move antiretroviral delivery from hospitals
to more peripheral health facilities or even beyond health facilities. This could increase the number of people with access to care, improve
health outcomes, and enhance retention in treatment programmes. On the other hand, providing care at less sophisticated levels in the
health service or at community-level may decrease quality of care and result in worse health outcomes. To address these uncertainties,
we summarised the research studies examining the risks and benefits of decentralising antiretroviral therapy service delivery.
Objectives
To assess the effects of various models that decentralised HIV treatment and care to more basic levels in the health system for initiating
and maintaining antiretroviral therapy.
Search methods
Weconducted a comprehensive search to identify all relevant studies regardless of language or publication status (published, unpublished,
in press, and in progress) from 1 January 1996 to 31 March 2013, and contacted relevant organisations and researchers. The search
terms included ’decentralisation’, ’down referral’, ’delivery of health care’, and ’health services accessibility’.
Selection criteria
Our inclusion criteria were controlled trials (randomised and non-randomised), controlled-before and after studies, and cohorts
(prospective and retrospective) in which HIV-infected people were either initiated on antiretroviral therapy or maintained on therapy
in a decentralised setting in lower- and middle-income countries. We define decentralisation as providing treatment at a more basic
level in the health system to the comparator.
Data collection and analysis
Two authors applied the inclusion criteria and extracted data independently. We designed a framework to describe different decentral-
isation strategies, and then grouped studies against these strategies. Data were pooled using random-effects meta-analysis. Because loss
to follow up in HIV programmes is known to include some deaths, we used attrition as our primary outcome, defined as death plus
loss to follow-up. We assessed evidence quality with GRADE methodology.
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Main results
Sixteen studies met the inclusion criteria, all but one were from Africa, comprising two cluster randomised trials and 14 cohort studies.
Antiretroviral therapy started at a hospital and maintained at a health centre (partial decentralisation) probably reduces attrition (RR
0.46, 95% CI 0.29 to 0.71, 4 studies, 39 090 patients, moderate quality evidence). There may be fewer patients lost to care with this
model (RR 0.55, 95% CI 0.45 to 0.69, low quality evidence).
We are uncertain whether there is a difference in attrition for antiretroviral therapy started and maintained at a health centre (full
decentralisation) compared to a hospital at 12 months (RR 0.70, 95% CI 0.47 to 1.02; four studies, 56 360 patients, very low quality
evidence), but there are probably fewer patients lost to care with this model (RR 0.3, 95% CI 0.17 to 0.54, moderate quality evidence).
When antiretroviral maintenance therapy is delivered at home by trained volunteers, there is probably no difference in attrition at 12
months (RR 0.95, 95% CI 0.62 to 1.46, two trials, 1453 patients, moderate quality evidence).
Authors’ conclusions
Decentralisation of HIV care aims to improve patient access and retention in care. Most data were from good quality cohort studies
but confounding between site of treatment and outcomes cannot be excluded. Nevertheless, this review found that attrition appears
to be lower in partial decentralisation models of treatment, where antiretrovirals were started at hospital and continued in the health
centre; with antiretroviral drugs started and continued at health centres, no difference in attrition was detected, but there were fewer
patients lost to care. For antiretroviral therapy provided at home by trained volunteers, no difference in outcomes were detected when
compared to facility-based care.
P L A I N L A N G U A G E S U M M A R Y
Providing antiretroviral therapy closer to patients homes to improve access to care in lower- and middle-income countries
Background
Many people living with HIV who need antiretroviral therapy are unable to access or remain in care. This is often because of the
time and cost required to travel to health centres. One approach to facilitating access and retention in care is to provide antiretroviral
therapy close to people’s homes, ‘decentralising’ treatment from hospitals to health centres or even to the community. We wanted to
assess whether decentralisation of antiretroviral therapy reduced the number of people lost to follow-up. Because loss to follow-up in
HIV programmes is known to include some people who have died, our main outcome of interest was ’attrition’, which is the number
of people who have either died or been lost to follow-up.
Study characteristics
We searched for studies up to March 2013. We found 16 studies, including two high quality randomised controlled trials and 14
studies collecting data from HIV care programmes. All but one study was conducted in Africa. The study participants included both
adults and children who were followed-up for up to two years.
We describe three types of care:
- Partial decentralisation: starting antiretroviral therapy at the hospital, then moving to a health centre to continue treatment
- Full decentralisation: starting and continuing treatment at a health centre
- Providing antiretroviral therapy in the community: antiretroviral therapy is started at a health centre or hospital and thereafter provided
in the community
Key results
We found that if antiretroviral therapy was started at a hospital and continued in a health centre (partial decentralisation), there was
probably less attrition and fewer patients were lost to care after one year (four studies, 39 090 patients).
Where antiretroviral therapy was started and continued at a health centre (full decentralisation), there was probably no difference in
the number of deaths and patients lost to follow-up (attrition), but overall, there were probably fewer patients lost to care after one year
(four studies, 56 360 patients).
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If antiretroviral therapy was provided in the community, by trained volunteers, there was probably no difference detected in death or
losses to care when compared to care provided at a health centre after one year (two studies, 1 453 patients).
Overall, none of the models of decentralisation led to worse health outcomes. The research indicates that fewer patients are lost to care
when they are continued on antiretroviral therapy at health centres rather than in hospitals. The research also did not detect a difference
in the numbers of patients lost to care when they are treated in the community rather than in a health facility.
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B A C K G R O U N D
Description of the condition
The spread and volume of HIV care and treatment services has in-
creasedmarkedly in lower- andmiddle-income countries (LMIC).
As of mid-2011, around 8 million people were receiving antiretro-
viral therapy (ART) in LMIC. In spite of considerable progress in
improving access to ART to date, global coverage for ART is still
around 50% (UNAIDS 2011). There is high-level political com-
mitment to provide ART to 15 million people by 2015, but the
current rate of enrolment of patients on ART may be insufficient
to reach the global goal, therefore, adaptations to service delivery
models are needed.
An effective service needs HIV testing and counselling services to
be linked to HIV care and treatment; requires ART initiation as
early as clinically indicated; and a service that retains patients. This
will help decrease AIDS-related morbidity and mortality, reduce
costs andmaximise efficiency gains, and avert new infections (Ford
2011). Yet there are a number of constraints at all of these steps.
Recent systematic reviews have indicated that, for those who do
initiate ART, retention in care is a major challenge, with around
25%of patients estimated to be lost to follow-upwithin 24months
of initiating ART (Fox 2010). Barriers to access to care appear to
be important drivers of poor retention, with transport costs, time
spent travelling to health facilities, and time waiting for services
at health facilities all cited as reasons for defaulting (Kagee 2011;
Miller 2010; Ware 2009).
Description of the intervention
In order to increase access to care - both to allowmore people to be
treated, and to improve retention among those in care - a number
of countries have introduced two important, linked adaptations to
the traditional, “Western-based” (i.e. hospital-based and doctor-
led) model of care provision:
• decentralisation of ART care delivery from hospitals to
more peripheral health facilities (this review).
• task shifting of treatment provision from highly trained
specialists and medical practitioners to nurses and other non-
physician providers (Kredo 2012).
Decentralisation of care broadly means relocating services from
centralised sites (i.e. hospitals) to peripheral health centres or lower
levels of healthcare, generally geographically closer to the homes of
patients. However, definitions of decentralised services vary con-
siderably, and “community,” “health post,” “health centre” and
“hospital services” all may vary in meaning between countries.
In this review, we define each “tier” in the health system according
to their staffing configuration (Table 1). Thus, for community,
care is provided by someone with only a few months training; for
a health centre, this is led by a paramedic or nurse; for a hospital,
it is led by a doctor or equivalent; and for an advanced hospital,
there are specialist doctors present. In the table we also define com-
munity in three categories: family member, village volunteer, or a
primary health care clinic with a nurse aide or community health
worker. At community care level, systems may thus be established
to deliver treatment at household level. This framework is to help
describe different programmes. For HIV care, the emerging mod-
els are giving rise to a variety of terms, such as “full decentral-
isation”, “partial decentralisation” (also sometimes referred to as
down referral) and “full decentralisation with regular hospital sup-
port”. To help classify models and allow cross study comparisons,
we have developed a nomenclature (Table 2). This is not meant to
be definitive and may need to be modified as the models of care
develop, but provides a working framework for this review.
Task shifting is related to decentralisation, and is the process
whereby specific tasks are transferred to different cadres of health
workers who have had less training and have fewer qualifica-
tions (WHO 2008).Task shifting is being addressed by a separate
Cochrane Review (Kredo 2012).
How the intervention might work
Decentralisation aims to increase access to care and improve health
outcomes, in particular retention in care. These benefitsmay result
from a number of factors, including the improved patient care by
nurses and counsellors due to lower workload (i.e. lower staff to
patient ratios) compared to centralised sites; and reduced time and
financial cost to patient due to greater proximity of services (Fatti
2010). On the other hand, there may be concern that providing
care at less sophisticated levels of the health system may decrease
quality of care and result in worse health outcomes (Decroo 2009).
As a result of these uncertainties, countries and regions vary in
the extent to which HIV/AIDS treatment is decentralised beyond
hospitals, and there is a need for clarity around the risks and ben-
efits of decentralising ART services in order to inform future op-
erational guidance.
O B J E C T I V E S
To assess the effects of decentralised HIV care in relation to initi-
ation and maintenance of antiretroviral therapy.
M E T H O D S
Criteria for considering studies for this review
Types of studies
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Randomised, non-randomised and controlled before-and-after
studies.
Prospective and retrospective cohort studies with a comparison
between standard and decentralised delivery. For cohort studies,
comparators needed to be contemporaneous (delivered at the same
time), in the same country, and geographically adjacent (i.e. within
the same district, or in adjacent districts within a province).
Types of participants
HIV-infected patients at the point of initiating treatment, and
patients already on treatment requiring maintenance and follow-
up.
Types of interventions
Any form of decentralised care delivery model for the initiation of
treatment, continuation of treatment, or both. Decentralisation is
defined as the provision of treatment at a more basic level in the
health system than the centralised site (Table 1), according to the
definitions described above (Table 2).
Control
Care delivered at the centralised site (usually a hospital, or in the
case of community interventions, any facility)
Types of outcome measures
Primary outcomes
• Attrition, defined as a composite of loss to follow-up or
death.
• Loss to follow-up at set time points after the intervention
has been introduced, as defined by the study authors.
• Death, after being considered eligible for treatment, or
during treatment.
Secondary outcomes
• Time to starting antiretroviral treatment.
• Patients diagnosed with tuberculosis after entry into HIV
care.
• Virologic response to ART (the proportion of participants
that reach or maintain a pre-defined level of viral load
suppression, as defined by the study authors).
• Immunologic response to ART (mean change in the
concentration of CD4+ lymphocytes from baseline, as expressed
in cells/mm3).
• Occurrence of a new AIDS-defining illness.
• Patient satisfaction with care, as defined by the study
authors. We will include qualitative data if available from the
included studies.
• Cost to the provider.
• Cost to the patient and family.
• Any negative impact on other programme and health care
delivery reported by the authors.
Search methods for identification of studies
See the Cochrane HIV/AIDS Group search strategy.
Electronic searches
In collaboration with the trial search coordinator of the Cochrane
HIV/AIDS Review Group, we developed a comprehensive search
strategy to identify all relevant studies regardless of language
or publication status (published, unpublished, in press, and in
progress). We searched from 1 January 1996 (the advent of triple-
drug ART) to 11 March 2013. We searched the following elec-
tronic databases:
• Cochrane Central Register of Controlled Trials
(CENTRAL) (Appendix 1)
• MEDLINE (Appendix 2)
• EMBASE (Appendix 3)
• LILACS
• CINAHL
• Web of Science
• WHO Index Medicus
Key words included MeSH terms and free-text terms relevant to
decentralisation, down referral, delivery of health care, health ser-
vices accessibility, and other relevant terms.
Searching other resources
Researchers and relevant organisations. We contacted individ-
ual researchers working in the field and staff of international organ-
isations including the Joint United Nations Programme on HIV/
AIDS (UNAIDS), and the World Health Organization (WHO),
and Médecins Sans Frontières (MSF) to identify studies either
completed or ongoing.
Reference lists.We checked the reference lists of all studies identi-
fied by the above methods and examined the bibliographies of any
systematic reviews, meta-analyses, or current guidelines identified
during the search process.
Ongoing studies.We searched the WHO International Clinical
Trials Registry Platform and clinicaltrials.gov search portals for in-
formation on unpublished and ongoing trials.
Data collection and analysis
Themethodology for data collection and analysis was based on the
guidance of Cochrane Handbook of Systematic Reviews of Interven-
tions (Higgins 2008). Abstracts of all trials identified by electronic
or bibliographic scanning was examined by two authors working
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independently. Where necessary, the full text was obtained to de-
termine the eligibility of studies for inclusion.
Selection of studies
We removed duplicate references using a reference management
software. Following this, aCochrane research specialist did a broad
review of results, excluding those that were clearly irrelevant. TK
and FBA independently selected potentially relevant studies by
scanning the titles, abstracts, and descriptor terms of the remain-
ing references and applied the inclusion criteria. We discarded ir-
relevant reports and obtained the full article or abstract for all
potentially relevant or uncertain reports. TK and FBA indepen-
dently applied the inclusion criteria using a standardised eligibility
form. Studies were reviewed for relevance, based on study design,
types of participants, exposures and outcomes measures. All au-
thors contributed to a consensus decision for any uncertainties or
disagreements about inclusion.
Data extraction and management
After initial search and article screening, two authors indepen-
dently double-coded and entered information from each selected
study onto standardised data extraction forms. Extracted informa-
tion included:
• Study details: citation, start and end dates, location, study
design and details.
• Participant details: study population eligibility (inclusion
and exclusion) criteria, ages, population size, attrition rate,
details of HIV care and disease progression and any clinical,
immunologic or virologic staging, tuberculosis or laboratory
information.
• Intervention details: level of health service, cadre of health
worker and other forms of patient support, including diagnosis
of tuberculosis.
• Outcome details: retention in care, mortality, tuberculosis
case finding, AIDS-related progression of disease, virological and
immunological outcomes, patient satisfaction, cost of care.
The interventions were carefully and systematically described to
ensure that all of the interventions and co-interventions that were
reported were captured.
Assessment of risk of bias in included studies
Two authors independently assessed the risk of bias within the in-
cluded studies against criteria described below in accordance with
methods recommended by the Cochrane Effective Practice and
Organisation of Care (EPOC) Group and the Cochrane Hand-
book for Systematic Reviews of Interventions (Higgins 2008). The
following judgments were used: low risk of bias, high risk of bias
or unclear risk of bias (either due to lack of information or uncer-
tainty over the potential for bias). We resolved disagreements by
consensus.
Randomised controlled trials and cohort studies:
Standard criteria are suggested for all randomised controlled tri-
als (RCTs), non-randomised controlled trials (NRCTs) and con-
trolled before-after studies (CBA studies) from the EPOC group.
Further information can be obtained from theCochraneHandbook
section on risk of bias (Higgins 2008a). We adapted these criteria,
referring to the Newcastle-Ottawa (Newcastle-Ottawa Scale) and
EPOC recommendations to best address the included studies and
potential risk of bias presented by them as follows:
1. Adequate generation of the allocation sequence [trials]
2. Adequate allocation concealment [trials]
3. Baseline CD4 count measurements were similar [all studies]
4. Other baseline characteristics were similar [all studies]
5. The study was adequately protected against contamination
[trials]
6. Data collection methods (i.e. retrospective of prospective)
[cohorts]
7. The study was free from other risks of bias [ we have
specified co-interventions as possibly introducing bias] [all
studies]
8. Patient selection bias [cohorts]
Assessment of overall quality of evidence We assessed the qual-
ity of evidence across particular models of care with Grading
of Recommendations Assessment, Development and Evaluation
(GRADE) methodology (Guyatt 2011), defining the quality of
evidence for each outcome as “the extent to which one can be
confident that an estimate of effect or association is close to the
quantity of specific interest” (Higgins 2008). The quality rating
across studies has four levels: high, moderate, low or very low.
Randomised controlled trials are initially categorised as provid-
ing high quality evidence, but the quality can be downgraded;
similarly, other types of controlled trials and observational studies
are categorised as providing low quality evidence but the quality
can be upgraded if justified. Factors that decrease the quality of
evidence include limitations in design, indirectness of evidence,
unexplained heterogeneity or inconsistency of results, imprecision
of results or high probability of publication bias. Factors that can
increase the quality level of a body of evidence include studies
with a large magnitude of effect, and studies in which all plausible
confounding would lead to an underestimation of effect.
Measures of treatment effect
We used Review Manager software (Review Manager 2011)
provided by the Cochrane Collaboration for statistical analysis
and GRADEpro software (GRADEpro 2008) provided by the
GRADEWorking Group to produce GRADE Summary of Find-
ings tables and GRADE Evidence Profiles. We summarised di-
chotomous outcomes for effect in terms of risk ratios (RRs) with
their 95% confidence intervals. We calculated summary statis-
tics using meta-analytic methods, presented as forest plots, and
presented findings in GRADE Summary of Findings tables and
GRADE Evidence Profiles for all critical outcomes of interest.
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Dealing with missing data
We contacted study authors to clarify data where needed, as in the
case of the Bock 2008; Fatti 2010; Kipp 2010 and Morsheimer
(unpublished) studies.
Assessment of heterogeneity
For the main outcomes death and loss to follow-up, we conducted
meta-analyses. We examined heterogeneity by using the χ2 statis-
tic with a significance level of 0.10, and the I2 statistic. We inter-
preted an I2 estimate of greater than 50% as indicating moderate
to high levels of heterogeneity (Deeks 2008).
Data synthesis
We grouped data by the tiers of service and care configurations
outlined in Table 1 and Table 2. The main comparisons for decen-
tralisation included partial decentralisation, full decentralisation
and referral to community maintenance care. When interventions
and study populations were sufficiently similar across the different
studies, we pooled the data across studies and estimated summary
effect sizes using random-effects models. We used the inverse vari-
ance method for analysis of cluster randomised designs.The in-
verse variance method assumes that the variance for each study is
inversely proportional to its importance, therefore more weight is
given to studies with less variance than studies with greater vari-
ance. We did not meta-analyse data where different study designs
were included, as the data were considered too heterogeneous for
pooling.
We summarised the quality of evidence for the studies separately
for each outcome, and for the different study designs, in the
GRADE Summary of Findings tables and GRADE Evidence Pro-
files (Guyatt 2011).
Subgroup analysis and investigation of heterogeneity
We examined outcomes under the three models of care: partial
decentralisation (initiated at hospital, continued at health centre),
full decentralisation (initiated and treated at health centre) and
community care for maintenance of ART (Table 2). We defined
hospital and health centre strictly as established in the protocol
(Table 1). Sub-groups were formed by duration of follow-up (i.e.
6 months, 12 months or 24 months).
Sensitivity analysis
A sensitivity analysis was conducted in which 40% of all patients
lost to follow-up were reclassified as being dead. This figure was
chosen because, according to a systematic review of HIV infected
patients in treatment programmes in low resource setting, 40% of
patients lost to follow-up were found upon tracing to have died
(Brinkhof 2009).
R E S U L T S
Description of studies
Results of the search
Searches were conducted inMay 2012 andMarch 2013 and iden-
tified 3437 titles (see prisma flow diagram Figure 1). Twenty-nine
full-text articles were closely examined by two authors (TK and
FBA), including a trial, identified by checking references; an un-
published study provided by the co-author, on hearing of this re-
view in progress, however this is awaiting further data before in-
clusion; and a further study was suggested through contact with
the technical team at the WHO.
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Figure 1. Study flow diagram.
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We finally identified two cluster randomised controlled trials and
14 cohort studies that met our inclusion criteria for data extrac-
tion, coding and potential meta-analysis. TK, FBA and NF inde-
pendently extracted data for the included studies.
Included studies
Sixteen studies met the inclusion criteria, two cluster randomised
controlled trials (Jaffar 2009; Selke 2010), two prospective cohorts
(Humphreys 2010;Kipp2010) and12 retrospective cohort studies
(Assefa 2012; Balcha 2010; Bedelu 2007; Bock 2008; Brennan
2011; Chan 2010; Fatti 2010; Fayorsey 2013; Hansudewechakul
2012; McGuire 2012; Massaquoi 2009; Odafe 2012).
Three studies took place in rural Malawi (Chan 2010; Massaquoi
2009;McGuire 2012), two in various settings including urban,
peri-urban and rural Ethiopia (Assefa 2012; Balcha 2010), two in
rural Uganda (Jaffar 2009; Kipp 2010), one in rural and urban
Kenya (Selke 2010), one in rural Swaziland (Humphreys 2010);
four in various settings including urban, peri-urban and rural set-
tings in South Africa (Bedelu 2007; Bock 2008; Brennan 2011;
Fatti 2010).One study examined data from five countries in Africa
(Kenya, Lesotho, Mozambique, Rwanda and Tanzania (Fayorsey
2013) and one from Thailand (Hansudewechakul 2012)
All studies evaluated decentralisation of care from hospital level
to more basic levels of care. In addition, eight studies included
task shifting from doctors to non-doctors (either nurses or clinical
officers): Assefa 2012; Bedelu 2007; Brennan 2011; Humphreys
2010; Jaffar 2009; Kipp 2010; Massaquoi 2009; and Selke 2010.
Three studies examined treatment in children only (Bock 2008,
Fayorsey 2013,Hansudewechakul 2012), two included adults and
children (Chan 2010 and Massaquoi 2009) and the rest included
adults only.
Finally, one additional study fromNigeria was included that com-
pared treatment at tertiary and secondary hospital care (Odafe
2012). Whilst it met our inclusion criteria, the model evaluated
was not considered directly relevant to the review question. Results
from this study are reported separately.
Interventions
The threemodels of decentralisation of care that were pre-specified
in the protocol (Table 2) were further elaborated while reviewing
the included studies as follows:
1. Partial decentralisation, in which ART is initiated in a hospital
setting and patients are down referred for follow-up at the health
centre (also sometimes referred to as “down referral”)
2. Full decentralisation, in which ART is initiated and maintained
at a health centre rather than a hospital
In both of these models of care the health care provider at the
health centre, or more basic level of care, was usually a nurse of
clinical officer (health officer), except in the case of the paediatric
studies in which doctors were generally providing care.
3. A community model, in which ART is initiated at the health
centre or hospital, but maintenance occurs at the home, supported
by community health workers
In this model, HIV care was delivered by community volunteers or
field officers with specific training, to ensure they could monitor
adherence, adverse effects and clinical symptoms at the home (e.g.
computer aided devices or checklists).
The models of care in included studies are described in detail
(Table 3) including relevant co-interventions such as additional
adherence support through peer educators, supervision on-site or
training for health workers.
Excluded studies
See Excluded studies
There were 13 excluded studies, nine of which were excluded on
the basis of their study design (cross-sectional surveys, qualitative
or no contemporary arm for comparison), and two because they
were conducted in high income countries.
Risk of bias in included studies
Modified risk of bias criteria were used to evaluate the included
studies. The criteria were developed to reflect the study designs in-
cluded in this review - prospective and retrospective cohort studies
and randomised controlled trials (including cluster randomised
controlled trials). See summary of risk of bias by study in Figure
2.
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Figure 2. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Randomised controlled trials
The two randomised controlled trials assigned interventions by
cluster (Jaffar 2009; Selke 2010). They were both well balanced
for baseline CD4+ cell count, an important indicator of baseline
morbidity, and were therefore rated as having a low risk of bias,
theywere also balanced for other baseline characteristics, including
sex, age and WHO clinical stage, also rated as contributing a low
risk of bias. Co-interventions used to support participants (such as
adherence support) were similar for both groups in the Jaffar 2009
and Selke 2010 trials and this was rated as having a low risk of bias.
Sequence generation was not described in either included trial and
therefore was rated as presenting an unclear risk of bias. Allocation
concealment was well described and was unlikely to introduce
bias, rated as a low risk of bias. Neither trial had any indication of
contamination and it was unlikely that those in the control group
were at risk of receiving the intervention. Overall, risk of bias was
low, as judged by the modified risk of bias assessment tool.
Cohort studies
Prospective design:
Only two of the 14 cohort studies were prospective (Humphreys
2010, Kipp 2010). The other 12 studies were retrospective cohort
studies, and therefore classified as high risk of bias for data collec-
tion.
Stated selection differential:
Chan 2010 stated that only stable patients were selected to receive
ART at the health centre; this study was therefore rated as having
a high risk of bias. No other selection bias was detected in any of
the other cohorts.
Baseline comparability:
For partial decentralisation, four cohort studies had comparable
CD4+ cell counts at baseline, with sicker children in the Bock
2008 study remaining at the hospital, and CD4+ cell count not
reported in Chan 2010. For other baseline variables, two studies
were not comparable, and one study did not report on other base-
line characteristics (Bock 2008). In Chan 2010, patients at pe-
ripheral units were “healthier”, which could lead to an erroneous
conclusion that peripheral units were just as good as hospitals; and
in Fatti 2010, where patients at peripheral units were sicker.
For full decentralisation, two cohort studies had comparable
CD4+ cell counts, three did not report this, and in two the CD4+
cell counts indicated the patients were healthier at the peripheral
units (Bedelu 2007; McGuire 2012). For other baseline factors,
four did not report this, and three were not comparable as they
reported that they included patients that were healthier at periph-
eral units (Massaquoi 2009; McGuire 2012; Odafe 2012).
For decentralisation from facility to community, all three studies
were ranked as low risk of bias for CD4+ cell count and other
baseline factors.
Effects of interventions
See: Summary of findings for the main comparison
Antiretroviral therapy initiated in a hospital, maintained at a
health centre for HIV infected patients; Summary of findings 2
Antiretroviral therapy started andmaintained in a health centre for
HIV infected patients; Summary of findings 3 Decentralisation
from the facility to the community for antiretroviral maintenance
therapy for HIV-infected patients on antiretroviral therapy
Studies reported retention variably, sometimes including patients
who were transferred out, but still in care, but this was not always
clearly reported. We were more consistently able to extract data
on whether patients were lost to care (defined within studies as
failure to attend clinic follow-up 3 months or 6 months after the
expected appointment date), and this was therefore chosen as a
more reliable measure than its inverse, retention. We also sought
data on mortality; however, the majority of the included stud-
ies did not trace patients who were lost to care to determine if
they were dead (and therefore classified as mortality) or alive and
truly lost to follow-up. This is a known problem with antiretro-
viral treatment programs with varying rates of mortality among
patients who default from care. A recent systematic review showed
a pooled mortality estimate of around 40% among HIV patients
on antiretroviral programs who were successfully traced following
default from care (Brinkhof 2009). We therefore report as our pri-
mary outcome the composite outcome of attrition (i.e. death or
lost to care).
MAIN ANALYSIS BY THE THREE
DECENTRALISATION MODELS
1. Partial decentralisation - Initiated antiretroviral
therapy at hospital and maintained in a health centre
See Summary of findings for the main comparison
There were no trials that examined this comparison. Data come
from six observational cohorts reporting outcomes for three time
points, including two cohorts of paediatric patients.
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Attrition (death or lost to care)
Partial decentralisation reduced attrition at 12 months (RR 0.46,
95%CI 0.29 to 0.71, four cohort studies, 39 090 patients, moder-
ate quality evidence, Figure 3). This benefit was consistent across
all the four studies included in this analysis.
Figure 3. Forest plot of comparison: 1 Partial decentralisation - initiation in hospital, maintenance at health
centre, outcome: 1.1 Death or lost to care (12 months).
Lost to care
See Analysis 1.2 and Figure 4
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Figure 4. Forest plot of comparison: 1 Partial decentralisation - initiation in hospital, maintenance at health
centre, outcome: 1.2 Lost to care.
Overall, partial decentralisation was found to lead to fewer num-
bers of patients lost to care at 12 months.
Two retrospective (Bock 2008; Fatti 2010) and one prospective
cohort (Humphreys 2010) contributed to the 6 month data, in-
cluding 28 699 patients in rural, peri-urban and urban settings.
Overall, from our unadjusted pooled analysis the relative risk of
patients lost to care is RR 0.99 (95% CI 0.56 to 1.76; I2 = 59%).
Four retrospective cohorts contributed data on patients lost to care
at 12months (Bock 2008; Brennan 2011; Chan 2010; Fatti 2010)
including 39 090 patients. Bock 2008 and Chan 2010 included
children in their study. Overall, patients were 45% less likely to
be lost to care at the decentralised site (RR 0.55, 95% CI 0.45
to 0.69; I2 = 77%). Thus there is low quality evidence that down
referral may decrease the numbers of patients lost to care at 12
months.
Finally, one retrospective study in children reported data on chil-
dren at 24 months (Hansudewechakul 2012), with no difference
between models of care (no patients lost to care at any site).
Mortality
See Analysis 1.3 and Figure 5
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Figure 5. Forest plot of comparison: 1 Partial decentralisation - initiation in hospital, maintenance at health
centre, outcome: 1.3 Death.
Overall, there is low quality evidence that partial decentralisation
of care after initiation at a hospital may reduce death at 12months.
The three cohorts reporting on patients lost to care at the clinic,
also provide data for mortality at six months (Bock 2008; Fatti
2010; Humphreys 2010) The pooled risk of death at six months
was RR 0.52 (95% CI 0.19 to 1.41; I2 = 82 %) .
The risk of bias inherent and reported in the cohort studies would
be expected to favour the intervention in all studies, except in Fatti
2010. There is overall very low quality data for this outcome at six
months, with wide confidence intervals.
The same four cohorts reporting losses to care at 12 months pro-
vide data for this outcome, with the same high potential risk of
bias. The relative risk of mortality at 12 months was RR 0.34
(95% CI 0.13 to 0.87). There was substantial quantitative and
qualitative heterogeneity, and an I2 of 98%, all of which was in-
troduced by one study (Fatti 2010), which may be explained by
the inclusion of patients with more advancedWHO clinical stages
in the control arm of the study. As the direction of bias favours
the intervention, the quality of the evidence was not downgraded
for methodological limitations. The studies, although clinically
heterogeneous, consistently favoured partial decentralisation, and
were therefore judged to have no serious inconsistency. In a sen-
sitivity analysis assuming 40% of patients lost to care had died,
mortality at 12 months remained lower at decentralised sites (RR
0.41, 95% CI 0.22 to 0.76).
Thus, overall there is low quality evidence that partial decentral-
isation of care reduces death at 12 months. This should be seen
in the context of substantial heterogeneity in the studies and high
risk of bias. Overall, there was no excess of deaths seen in any
of the studies with care decentralised to the health centres, after
initiation at hospital level.
Finally, one study, done among children, reported lower mortality
at the decentralised site at 24 months (RR 0.04, 95%CI 0.00 to
0.58) (Hansudewechakul 2012).
2. Full decentralisation - Initiated and maintained
antiretroviral therapy at a health centre
See Summary of findings 2
No trials examined this comparison. Data come from six observa-
tional cohorts reported outcomes at three time points, including
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one cohort of paediatric patients.
All studies included patients in rural settings. Antiretroviral ther-
apy was initiated and maintained at the health centres and deliv-
ered by nurses or clinical officers, not doctors.
Attrition (Death or lost to care)
Overall, decentralisation to heath centres for initiation and main-
tenance of care appeared to reduce attrition at 12 months (RR
0.70, 95% CI 0.47 to 1.02, four cohort studies, 56 360 patients,
very low quality evidence, Figure 6). This result was consistent
across three of the studies included in the analysis while the fourth
study showed no difference in attrition.
Figure 6. Forest plot of comparison: 2 Full decentralisation - initiation and maintenance in health centre,
outcome: 2.1 Death or lost to care (12 months).
Lost to care
See Analysis 2.2 and Figure 7
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Figure 7. Forest plot of comparison: 2 Full decentralisation - initiation and maintenance in health centre,
outcome: 2.2 Lost to care.
Overall there was moderate quality evidence that full decentrali-
sation of care from hospitals to health centres for both initiation
and maintenance of HIV care probably reduces the numbers of
patients lost to care at 12 months.
Two large retrospective cohorts, one from Ethiopia (Assefa 2012)
and another fromMalawi (McGuire 2012) both reported a statis-
tically significant reduction in patients lost to care at decentralised
sites at six months, and the pooled relative risk, indicated a large
reduction of 47% in the risk of being lost to care (RR 0.53, 95%
CI 0.26 to 1.10, 51 261 patients).
There was also a reduction in the risk of patients being lost to
care at decentralised sites at 12 months, with consistent reductions
reported across four cohorts and a strong association reporting a
reduction of 70% (RR 0.3, 95%CI 0.17 to 0.54, 56 360 patients)
when pooling the data. A consistent benefit was also reported by
four studies that reported lost to care at 24 months (RR 0.50,
95%CI 0.36 to 0.71, 61 445 patients).
Mortality
See Analysis 2.3 and Figure 8.
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Figure 8. Forest plot of comparison: 2 Full decentralisation - initiation and maintenance in health centre,
outcome: 2.3 Death.
Overall, there is very low quality evidence that there was no dif-
ference in mortality for patients treated at the health centre or the
hospital at 12 months.
The pooled risk of death in decentralised sites was (RR 0.84,
95%CI 0.35 to 2.00, two studies, 50 000 patients) at six months,
(RR 1.10, 95%CI 0.63 to 1.92, four studies, 55 099 patients) at
12 months, and (RR 0.64, 95%CI 0.39 to 1.06, four studies, 60
184 patients) at 24 months. Although baseline CD4+ cell counts
were similar between some groups, the studies were judged to have
unclear bias related to co-interventions and other baseline charac-
teristics, as these were not well reported. In the sensitivity analysis,
mortality at 12 months remained similar between sites (RR 0.86,
95% CI 0.58 to 1.29).
Other models of full decentralisation
Odafe 2012 examined attrition, death and loss to follow-up of
patients treated in secondary and tertiary providers in Nigeria.
Whilst this loosely could be a study of “decentralisation” it was
at a higher level of care and is not a current question for most
health care systems in countries of Africa, where HIV treatment
is currently standard at secondary level.
3. Decentralisation to the community - maintained
on antiretroviral therapy in the community
Summary of findings 3
Two trials examined this comparison. Data come from these two
trials and one observational cohort reporting outcomes at three
time points.
All studies included patients in rural settings. Antiretroviral ther-
apy was initiated at the health centres and maintained in the com-
munity with a trained community health worker.
Attrition (Death or lost to care):
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Neither trial provided adjusted rates for analysis, therefore in order
to adjust for the design effect, we required an intra-cluster co-ef-
ficient (ICC). We made a statistical assumption and used a liberal
ICC of 0.05. Following this adjustment, the included studies had
small sample sizes and wide confidence intervals, the evidence was
thus downgraded for imprecision. Overall, there is moderate qual-
ity evidence that there is probably no difference in attrition rates at
12months comparing community and facility-basedmaintenance
care (RR 0.95, 95%CI 0.62 to 1.46, two trials, 1453 participants,
Figure 9).
Figure 9. Forest plot of comparison: 3 Decentralisation - from the facility to the community for
antiretroviral maintenance therapy, outcome: 3.1 Death or lost to care (12 months).
Lost to care
See Analysis 3.2 and Figure 10
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Figure 10. Forest plot of comparison: 3 Decentralisation - to community from facility, outcome: 3.2 lost to
care.
Two cluster randomised controlled trials (Jaffar 2009; Selke 2010)
and a single cohort (Kipp 2010) provided the 6 and 12 month
data for patients who were lost to follow-up in the community.
Overall, there was moderate quality evidence from the two cluster
trials reporting that there was no difference at 12 months.
One prospective cohort reported on lost to care at 6months (Kipp
2010).Overall the risk of bias in this included studywas low. There
was no difference in the rate of failure to attend follow-up between
the groups (RR 1.49, 95% CI 0.81 to 2.74, 385 participants).The
same cohort also reported data at 24 months, and again the result
was not significantly different between models (RR 0.74, 95%CI
0.46 to 1.20, 385 participants).
This lack of difference was also supported by data from the two
randomised controlled trials at 12 months (RR 0.81, 95% CI
0.3 to 2.21, 1453 participants).The quality of the evidence was
downgraded for imprecision due to the low event rates in both
arms of both trials and wide confidence interval when combining
these two trials.
Mortality
See Analysis 3.3 and Figure 11
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Figure 11. Forest plot of comparison: 3 Decentralisation - to community from facility, outcome: 3.1 Death.
There was moderate quality evidence that rates of death at 12
months were similar whether maintenance care was delivered at
the facility or in the community (RR 1.03, 95% CI 0.64 to 1.65,
two trials, 1453 participants). Similarly, the risk of death was not
significantly different in the cohort study at six months (RR 1.44,
95%CI 0.81 to 2.57, one study, 385 participants) and 24 months
(RR 1.50, 95%CI 0.91 to 2.47, one study). All results of the
sensitivity analysis were non-significant (results not shown).
OTHER OUTCOMES
Studies reported on a variety of other outcomes that are reported
below.
Immunological changes - CD4+ cell count
Twelve cohorts report on change in CD4+ count, six provide me-
dian change at either six or 12 months (Assefa 2012; Balcha 2010;
Brennan 2011; Jaffar 2009; Hansudewechakul 2012; Kipp 2010).
As the studies reporting this outcome differed by model of care,
time of reporting or threshold, this outcome is reported narra-
tively. For all of these studies there is a consistent report of an in-
crease in CD4+ cell count, with no statistical difference between
decentralised or standard hospital treated groups.
Viral load suppression
Eight studies report the proportion of patients who are viro-
logically suppressed (Bedelu 2007; Brennan 2011; Fatti 2010;
Hansudewechakul 2012; Jaffar 2009; Kipp 2010; Selke 2010).
The reported virological suppression rates were similar across the
decentralised and control groups across these varied studies which
could not be meta-analysed.
Cost to providers and patients
One prospective cohort, Humphreys 2010, reports specifically on
the cost of travel for patients (Analysis 1.4). The average cost for
a decentralised patient was USD 0.74 compared to USD 1.5 for
a patient seen at the hospital (P = 0.001).
Two studies provided data on overall cost to patient (Analysis 3.4).
Both reports come from community-based treatment compared
to standard hospital-based treatment (Jaffar 2009; Kipp 2010).
Both studies indicate substantial increase in cost to patient when
they are required to travel to the hospital, which is usually further
from their homes. Kipp 2010 reports a doubling of cost to patients
when accounting for transport only. Jaffar 2009, the cluster trial,
reports a three times increase in costs, including transport, lost
work time, child-care costs and food.
Costs to the health service are also reported. Jaffar 2009 reported
costs to health service for community versus hospital-based groups.
These included staff, transport, drugs, laboratory, training, super-
vision, capital and utilities costs and was a mean of US$ 793 / year
for each patient in the home-based group compared to US$ 838
/ year / patient in the hospital-based group.
Initiation of tuberculosis treatment, time to initiation of ART, new
AIDS defining illness, any negative impact on the health delivery
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No study reported data on initiation of tuberculosis treatment, or
time to initiation of antiretroviral treatment. Selke 2010 reported
onnewWHOclinical stage 3or 4diseases, indicatingnodifference
between groups in these reported clinical events.No study reported
information indicating a negative impact on healthcare delivery.
Patient satisfaction with care
Assefa 2012 and Humphreys 2010 included a qualitative compo-
nent to their studies which reports on patient satisfaction with the
model of care by group.
Assefa 2012 evaluated patient satisfaction with care by conducting
two hour long focused group discussions (57 patients in 7 groups).
This study looked predominantly at the issue of task shifting and
its acceptability amongst patients and healthcare providers. Pa-
tients reported that nurse and health officer (clinical officer) ser-
vices were ’generally well accepted, and reduced waiting time’,
they also reported that they were ’more comfortable with nurses
than with physicians because nurses were friendlier and more sup-
portive’. Patients emphasised that nurses and health officers spent
more time with them discussing their medical problems and took
enough time examining them. Patients identified three additional
benefits of being involved in ART delivery: their life experience
helped them to provide appropriate counselling; it helped combat
stigma and discrimination in society; and it provided them with
an opportunity for employment. In the same study, focused-group
discussions were held with programme managers and healthcare
providers who agreed the model including task shifting provided
a timely solution for Ethiopias needs. They also agreed that nurses
and health officers can provide high quality care given adequate
training and supervision.
Humphreys 2010 was a prospective cohort that used the model of
down referral and included the assessment of patient satisfaction as
a primary outcome. Those attending the intervention clinic were
asked about their level of satisfaction, and 25 of the 31 respondents
said that they were very satisfied with the care received. Reasons
provided included the reduced cost of transport, being nearer to
home, shorter queue, being treated better by staff, receiving better
care and that theywould not be talked about. The two respondents
who were not satisfied with the care complained about the lack of
doctor, saying they did not have money to get to the main clinic,
and that there was a delay because staff from the hospital arrived
late at the health centre.
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D I S C U S S I O N
Summary of main results
Three models of care were assessed in the included studies of this
review.
In the first model, antiretroviral therapy is initiated at a hospital,
and maintained at a health centre (partial decentralisation). When
pooling the data, we found moderate quality evidence, favouring
lower rates of patient attrition, and low quality evidence of lower
rates of patients lost to care and mortality at 12 months (four
observational studies). Although the results of the meta-analysis
report lower risk of death and better follow up rates at the health
centres, there is substantial uncertainty about these results.
In the second model antiretroviral therapy is initiated and main-
tained at the health centre (full decentralisation). Our meta-anal-
ysis found moderate quality evidence of lower rates of patients lost
to care at the health centre compared to the hospital at 12 months
(four observational cohorts). The observational cohort data was
upgraded due to the large association reporting a 70% (95% CI
0.17 to 0.54) relative risk reduction in patients lost to care if they
attended the health centre, rather than the hospital, for HIV ser-
vices. There is however the possibility that additional evidence will
substantially alter this result. There is very low quality evidence
that attrition or death differed between arms whether care was de-
livered at the hospital or health centre. The quality of the data was
downgraded for methodological limitations, as patients tended to
be sicker at the hospital, favouring the intervention. These results
were also consistent for paediatric populations.
For the thirdmodel, community volunteers with basic training de-
livered antiretroviral healthcare to participants at their homes (two
cluster randomised controlled trials). We found moderate quality
evidence reporting no difference for death or losses to care at 12
months of follow-up. The risk of bias in the trials was overall low.
Overall we have moderate confidence that there is no difference
in these outcomes when community care is introduced, but there
is the possibility that further trials may change the results.
With respect to other relevant outcomes, the cohorts reporting
CD4+ cell counts showed increases in immunological status, but
no difference between models of care was found. Similar results
were found for changes in viral load, a marker of the effectiveness
of antiretroviral therapy, with studies reporting comparable viro-
logical suppression regardless of the model of care employed.
Costs, reported by three studies are considerably reduced in de-
centralised care for both the patient and provider making decen-
tralisation an attractive option for patients, and possibly assisting
in uptake of care closer to home. This is also reflected in the high
level of acceptability to patients reported by the two studies in
which this was assessed.
Overall completeness and applicability of
evidence
There is a recognised need to address HIV health service delivery
backlogs and ensure expanded access to HIV care. For this rea-
son, several governments and implementing partners have imple-
mented a decentralised approach to care. The majority of the data
included in this review were from retrospective cohorts describing
programmes that have rolled out across sub-Saharan Africa using
facility-basedmodels utilising lower levels of health care, and often
accompanied by task shifting to non-doctors for ART provision.
Retrospective data have several inherent biases. A key concern for
the interpretation of these studies is that individuals could choose
whether to be down-referred or not, or their healthcare provider
could allocate them according to both objective and subjective
assessments, but the methods for this decision was not always
clearly reported. In addition, the quality of data collection in these
studies is variable, and generally based on a secondary analysis of
routinely collected programme data. Another concern is that the
models of care, includinghealthcare provider, training, supervision
andmentoringprovided and the necessary organisational planning
that is required, were likely to differ across the studies. Evenwithin
the cohorts, there is a possibility that decentralisation did not
occur in a systematic way. These are pragmatic issues that a study
design that includes randomisation and concealed allocation of the
intervention could address to provide higher quality evidence. The
community models of care were evaluated using the cluster trial
design which provides moderate quality evidence that community
ART delivery can result in acceptable outcomes.
An important limitation of the evidence base, particularly for ob-
servational studies, is the potential for misclassification of deaths
among patients who are reported as lost to care. A meta-analysis
assessing this issue found that in studies that traced patients who
were lost to care to determine their outcomes, 20% to 60% had in
fact died (Brinkhof 2009). For this reason we include sensitivity
analyses to account for possible deaths amongst those described as
lost to care.
Finally, more information is needed on the package of care pro-
vided, including training and supervision, to support decentrali-
sation of ART services, particularly to the community.
Quality of the evidence
In the GRADE system, well-conducted randomised controlled
trials (without additional limitations) provide high quality evi-
dence, andobservational studieswithout any special strengths (and
without additional limitations) provide low-quality evidence. The
quality of evidence provided by a body of literature comprised ex-
clusively of observational studies would thus generally be graded
as low, except in circumstances where observational studies are
upgraded.
This review largely comprises observational data, and we found
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that the quality of evidence reported for the facility based mod-
els of decentralisation of care was generally low or very low. Two
exceptions to this were the outcome describing attrition in partial
decentralisation and patients lost to care utilising the full decen-
tralisation model where there was moderate quality evidence. This
data was upgraded from ’low’ due to the large effect size.
The model of care evaluating community follow-up by trained
field officers, including two high quality cluster randomised con-
trolled trials provided moderate quality evidence that the care pro-
vided by clinicians or field officers was similar in terms of the rate
of patients lost to care and death. The data was downgraded due
to the low event rate across arms.
Potential biases in the review process
Biases in the review process were minimised by performing a com-
prehensive search of databases and conference proceedings, not
limiting for language or time. In addition, we contacted expert
researchers in the field and other experts associated with relevant
organisations (e.g. WHO, MSF) for unpublished and ongoing
studies. We did not explore publication bias by using funnel plots
as there were too few studies to draw conclusions from this anal-
ysis.
Agreements and disagreements with other
studies or reviews
To date this is the first systematic review evaluating decentralisa-
tion of ART care. Prior and ongoing reviews have evaluated task
shifting, which is related to decentralisation in that lower-level
health services are generally staffed by lesser-trained health work-
ers. The findings of this review broadly agree with the task shifting
reviews which have found similar outcomes comparing physician
and non-physician led care.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
The research to date provides no evidence that anymodel of decen-
tralisation leads to a deterioration in health outcomes. Thus clin-
icians can be reassured that provision of HIV treatment at lower
levels in the health system does not necessarily lead to a serious
reduction in the quality of clinical care.
What is more, the findings of this review indicate that in some
settings the loss to care is reduced, which is consistent with treat-
ment being more accessible.
More broadly, studies show that decentralisation to lower levels
in the health care system is feasible. The studies were of a rea-
sonable size. Nevertheless, they were in the context of a range of
support structures and investments to ensuring delivery, includ-
ing training, supervision and additional devices such as computer-
aided or checklist-based decision aids. Thus, policy makers and
programme managers need to take into account adequate super-
vision and support when organising widespread delivery of HIV
care through the more basic tiers in the health system. This would
include referral systems to facilities being in place for those pa-
tients who experience complications. Importantly, several studies
provide data indicating reduced costs for both patients and ser-
vices when patients attend facilities closer to their homes.
Implications for research
Additional high quality evidence from trials and prospective co-
horts would provide valuable insight on the key outcomes includ-
ing retention in care, survival, quality of care and costs of decen-
tralising care from hospitals to other tiers of the health care sys-
tem. Implementation science research, using pragmatic trial de-
signs would be helpful in testing the types of packages of care that
best suit various settings and provide high quality care at decen-
tralised sites.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Assefa 2012
Methods Design: Retrospective cohort
Duration of study: Recruitment Sept 2006-2008, censoredMarch 2009 (minimum6months,
maximum 24 months follow-up)
Participants Country: Ethiopia
Setting: Nationwide, 30 hospitals, 25 health centres
Inclusion and exclusion criteria: None described
Comparable CD4 count or clinical stage at baseline: Similar CD4 count
Interventions Intervention: Patients initiated and maintained at health centres by nurses and health officers.
Severe manifestations, treatment failures were referred to hospital
Control: Initiated and followed up at hospital with physicians
Co-interventions: Community health workers performed counselling, referrals and linkage
between facilities and defaulter tracing, not clear if this was provided at all sites
Outcomes Mortality, loss to follow-up, retention, and median CD4+ cell count,
Assessed at 6, 12 and 24 months
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Baseline CD4 count (All studies) Low risk Similar median CD4 counts at baseline in
both groups
Other baseline variables (All studies) Unclear risk Not described
Co-interventions (All studies) Unclear risk Community health workers delivered adher-
ence and referral services from health centres
to hospitals, unclear whether this was for both
groups for the health centre group only
Data collection (Cohorts) High risk Retrospective cohort
Patient selection bias (Cohorts) Low risk Randomly selected folders in all included sites
in both groups
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Balcha 2010
Methods Design: Retrospective cohort
Duration: February 2007 - February 2009, 6 months post censor follow-up
Participants Country: Ethiopia
Setting: Rural and urban, in one region, 3 health centres, 2 hospitals
Inclusion criteria: Adults eligible for antiretroviral treatment (CD4 <200cell/mm3 or WHO
clinical stage 3 or 4) and on treatment for < 6 months
Exclusion: HIV infected, but not on antiretroviral therapy
Comparable CD4 count or clinical stage at baseline: Similar CD4 count
Interventions Intervention: Initiation on antiretrovirals in health centre, maintenance in health centre;
provided by nurses and health officers
Control: Initiated and maintained in hospital, provided by doctors
Co-interventions: None described
Outcomes Currently alive and on treatment, loss to follow-up, transferred out, mortality
Assessed at 24 months
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Baseline CD4 count (All studies) Low risk Similar median CD4 in both groups
Other baseline variables (All studies) Unclear risk Only data on sex reported by arm
Co-interventions (All studies) Unclear risk No co-intervention information described
Data collection (Cohorts) High risk Retrospective cohort
Patient selection bias (Cohorts) Low risk No selection bias identified
Bedelu 2007
Methods Design: Retrospective cohort
Duration: January 2004 - June 2005, completed 12 months follow-up by July 2006
Participants Country: South Africa
Setting: Rural, 12 health centres, 1 hospital
Inclusion criteria: Adults, eligible for ART CD4+ cell count < 200cells/mm3, WHO clinical
stage 4
Exclusion criteria: None described
Comparable CD4+ cell count or clinical stage at baseline: CD4+ cell counts differed at baseline
(sicker at hospital)
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Bedelu 2007 (Continued)
Interventions Intervention: ART initiated and maintained at health centre by nurses, physician support
with mobile team, adherence counsellors and patient support groups available
Control: ART initiated and maintained at hospital by doctors
Outcomes Mortality, loss to follow-up, CD4 count, viral load
Assessed at 12 months
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Baseline CD4 count (All studies) High risk CD4+ cell counts differed between groups at
baseline, lower CD4+ cell counts remained at
the hospital
Other baseline variables (All studies) Unclear risk Only reported on sex of included participants
Co-interventions (All studies) High risk Model differed by group: The health centre
group received additional adherence support
and visits from a mobile support team of ex-
perienced clinicians
Data collection (Cohorts) High risk Retrospective cohort
Patient selection bias (Cohorts) Low risk No selection bias identified
Bock 2008
Methods Design: Retrospective cohort
Duration: April 2004 - April 2006, no follow-up post censor described
Participants Country: South Africa
Setting: Urban, peri-urban, 20 health centres (enhanced), 16 hospitals, 3 advanced hospitals
Inclusion criteria: Children <15 years, eligible for ART (modified WHO stage 2, 3 disease, or
low CD4% by age group - <20% if <18 months old, or <15% if >18 months old), recurrent
hospitalisation >4 weeks, and identifiable caregiver
Exclusion criteria: Previous exposure to ART for >1 month (treatment experienced), trans-
ferred in or out of antiretroviral treatment site
Comparable CD4+ cell count or clinical stage at baseline: Sicker children with lower CD4 %
at hospital and advanced hospital
Interventions Intervention (Primary health care clinics): ART initiated at advanced hospital, maintained at
enhanced health centres, by doctors
Intervention (Level 1 district hospitals): ART initiated at advanced hospital, maintained at
hospital, by doctors
Control (level 2 and 3 facilities): ART initiated and maintained at advanced hospital, by
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Bock 2008 (Continued)
doctors and specialists
Outcomes Death, loss to follow-up, virological suppression, CD4 % changes, change to second line
treatment
Assessed at 6, 12 and 18 months
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Baseline CD4 count (All studies) High risk Sicker children with lower CD4% at hospital
and advanced disease remained in hospital
Other baseline variables (All studies) Unclear risk Not described
Co-interventions (All studies) Unclear risk Not described
Data collection (Cohorts) High risk Retrospective cohort
Patient selection bias (Cohorts) Low risk Although stable patients could be transferred
to the PHC group while sicker children re-
quiring specialist care were transferred to ad-
vanced hospital, this group of patients were
excluded from the analysis
Brennan 2011
Methods Design: Retrospective matched cohort analysis
Duration: April 2004 - January 2009
Participants Country: South Africa
Setting: Peri-urban, urban, 1 hospital, 1 clinic
Inclusion criteria: Stable on antiretroviral treatment for at least 11 months, no opportunistic
infections, CD4+ cell count > 200cells/mm3, stable weight and virologically suppressed <400
copies/mL. Considered good candidates by doctors and agree to down-referral
Exclusion criteria: Refused down referral
Comparable CD4 count or clinical stage at baseline: Control matched on sex, age, months
on therapy, treatment regimen, BMI, HB and CD4+ cell count (propensity scoring)
Interventions Intervention: ART initiated at advanced hospital by doctors, maintained at health centre by
nurses, seen every 2 months for medicine pick up. “Up referred” if default (>7 days), toxicity,
detectable viral load
Control: ART initiated and maintained by doctor at advanced hospital, seen 6 monthly, pick
up medicines every 2 months
Co-interventions: Adherence counselling provided at both facilities
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Brennan 2011 (Continued)
Outcomes Death, loss to follow-up, mean CD4+ cell count, viral load rebound
Assessed at 12 months
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Baseline CD4 count (All studies) Low risk Matched by propensity scores on all baseline
characteristics
Other baseline variables (All studies) Low risk Matched by propensity scores on all baseline
characteristics
Co-interventions (All studies) Low risk Both groups received adherence counselling
Data collection (Cohorts) High risk Retrospective cohort
Patient selection bias (Cohorts) Low risk All participants were equally eligible for down
referral, and were matched using propensity
scores on baseline characteristics
Chan 2010
Methods Design: Retrospective cohort
Duration: October 2004 - 31 December 2008, censored 31 December 2008, maximum
follow-up 50 months
Participants Country: Malawi
Setting: Rural, Zomba district, 16 health centres and 1 hospital
Inclusion criteria: Adults and older children eligible for antiretroviral therapy (CD4+ cell
count <250 cells/mm3, WHO clinical stage 3 or 4), on treatment for >3 months and stable,
no evidence of opportunistic infections or drug intolerance, provider confidence in patient
adherence, live closer to health centre than hospital
Exclusion criteria: None described
Comparable CD4+ cell count or clinical stage at baseline: Earlier stage disease at intervention
site, more men, children and advanced disease at control site
Interventions Intervention: ART initiated at advanced hospital, maintained at health centre, seen by nurses
and clinical officers, home-based peer support and health surveillance assistants for defaulter
tracing, expert patients, nutrition counsellors, volunteers from the community
Control: ART initiated and maintained at hospital, by clinical officers, adherence counsellor
and specialist support
Co-intervention: Paediatric and adult specialist support at both sites
Outcomes Death, loss to follow-up (not seen at facility for >3m)
Unknown time of outcome reporting
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Chan 2010 (Continued)
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Baseline CD4 count (All studies) Unclear risk Not reported
Other baseline variables (All studies) High risk Healthier at peripheral site: Earlier WHO
stage, more women and adults, differing base-
line characteristics
Co-interventions (All studies) High risk Paediatric and adult specialist infectious dis-
eases support at both sites, via mobile visits
for health centres. In addition, the interven-
tion group had many antiretroviral therapy
counsellors health surveillance assistants, peer
home based care providers and community
volunteers to support adherence
Data collection (Cohorts) High risk Retrospective cohort
Patient selection bias (Cohorts) High risk Only stable patients, on treatment for > 3
months with no opportunistic infections or
signs of adverse effects of the medication were
decentralised to intervention arm
Fatti 2010
Methods Design: Retrospective cohort
Duration: December 2004 - December 2007, followed up until March 2008
Participants Country: South Africa
Setting: Four provinces, peri-urban and rural, 47 health centres (enhanced), 9 hospitals and
3 advanced hospitals
Inclusion criteria: Adults >16 years with CD4+ cell count <200cells/mm3 or WHO clinical
stage 4, documented date of birth, gender and date of starting antiretroviral therapy
Exclusion criteria: Missing demographic data, antiretroviral therapy experienced, starting
antiretroviral therapy after 31 December 2007
Comparable CD4 cell count or clinical stage at baseline: CD4+ cell count clinically similar at
baseline (median range 109-113 cells/mm3), but more advanced disease (WHO clinical stage
3 or 4) at primary care facilities
Interventions Intervention: ART initiated at hospital by doctor and maintained at health centre (enhanced)
by doctors
Control: ART initiated and maintained at hospital by doctors
Co-interventions: Adherence counselling by community support workers
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Fatti 2010 (Continued)
Outcomes Death. loss to follow-up, virological suppression
reported at 12, 24 and 36 months
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Baseline CD4 count (All studies) Low risk Similar CD4+ cell counts between groups
Other baseline variables (All studies) High risk Health centres had patients with more ad-
vanced disease by WHO clinical stage (note
bias in favour of control)
Co-interventions (All studies) Low risk Adherence support provided by commu-
nity-based adherence counsellor, linking with
losses and detecting deaths
Data collection (Cohorts) High risk Retrospective cohort
Patient selection bias (Cohorts) Low risk No evidence of patient selection bias
Fayorsey 2013
Methods Design: Retrospective cohort
Duration:January 2008 to March 2010
Participants Country: Kenya. Lesotho, Mozambique, Rwanda and Tanzania
Setting: 274 sites, all receiving funding from the Presidents Emergency Plan for AIDS Relief
Inclusion criteria: Children < 15 years old
Exclusion criteria: if initiated on therapy before study period or at another facility they were
excluded from analysis
Comparable CD4 cell count or clinical stage at baseline: no data on CD4 counts at baseline
or other health related variables
Interventions Intervention: ART initiated and maintained at health centres by doctor or nurse (43%)
Control: ART initiated and maintained at hospital by doctors or nurse (42%)
Co-interventions:differed by country and site and included nutrition support, outreach ser-
vices, support groups, PEER educator programme and adherence counselling
Outcomes Loss to follow-up (not having made a clinic visit or pharmacy pick up in 90 days); mortality
(documented death in clinic records)
Notes Primary health facilities (health centres in our model) included health centres and clinics,
secondary health facilities (hospitals) included district, sub-district and provincial hospitals
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Fayorsey 2013 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Baseline CD4 count (All studies) Unclear risk Not stated
Other baseline variables (All studies) Unclear risk None provided
Co-interventions (All studies) High risk Variable by country and setting, therefore not
known
Data collection (Cohorts) High risk Retrospective cohort
Patient selection bias (Cohorts) Low risk No evidence of selection bias
Hansudewechakul 2012
Methods Design: Retrospective cohort
Duration: February 2002 to April 2008
Participants Country: Thailand
Setting: Community-based paediatric HIV care and treatment network, training and super-
vision were provided
Inclusion criteria: Children, stable on treatment prior to referral (absence of opportunistic
infections and improved weight and CD4%)
Exclusion criteria: ART experienced, follow up < 6 months, opportunistic infections, on
protease inhibitor
Comparable CD4 cell count or clinical stage at baseline: Median CD4% and viral load was
similar, but more CDC stage C at health centre (25% at hospital and 40% at health centre)
Interventions Intervention: ART initiated at hospital by doctors and maintained at health centres by nurses,
under doctor attendance
Control: ART initiated and maintained at hospital by doctors
Co-interventions: Team includednurses/ counsellors, people livingwithHIV, pharmacists and
physicians, adherence monitoring conducted at both sites. This model included mentoring,
emails, phone calls and discussion between health centres and hospital
Outcomes Mortality, loss to follow-up, weight for age score, adherence, CD4%, viral load change
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Baseline CD4 count (All studies) Low risk Balanced CD4% at baseline
41Decentralising HIV treatment in lower- and middle-income countries (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Hansudewechakul 2012 (Continued)
Other baseline variables (All studies) Low risk Baseline variables balanced.
Co-interventions (All studies) Low risk There was mentoring and support for health
centres health staff maintaining ART, how-
ever this is part of the model of care and not
expected to bias the results
Data collection (Cohorts) High risk Retrospective cohort
Patient selection bias (Cohorts) Low risk Stable patients were referred to the health cen-
tres, however, the analysis excluded patients
who were ill with opportunistic infections,
or who were on a protease inhibitor, and the
baseline characteristics were similar
Humphreys 2010
Methods Design: Prospective cohort
Duration: Started recruitment January 2007 - June 2007, followed up until November 2007,
minimum 6 months follow-up
Participants Country: Swaziland
Setting: Rural setting, one district hospital, 30 nurse led health centres
Inclusion criteria: Adults >14 years on antiretroviral therapy for at least 4 weeks, CD4+ cell
count >100 cells/mm3
Exclusion criteria: refused to be down referred
Comparable CD4+ cell count or clinical stage at baseline: CD4+ cell count and clinical stage
similar at baseline
Interventions Intervention: ART initiated at hospital by doctor and maintained at health centre by nurses
Control: ART initiated and maintained at hospital by doctors
Co-interventions: Training for primary care centre nurses, monthly outreach support visit by
at least one counsellor and nurse
Outcomes Clinic attendance, patient experience, loss to follow-up, change in CD4 count, weight, death
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Baseline CD4 count (All studies) Low risk Similar mean CD4+ cell counts between
groups
Other baseline variables (All studies) Low risk Age, sex, and weight were similar at baseline
42Decentralising HIV treatment in lower- and middle-income countries (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Humphreys 2010 (Continued)
Co-interventions (All studies) Unclear risk No additional intervention described, other
than mobile support team visits monthly
which are part of the model of care
Data collection (Cohorts) Low risk Prospective Cohort
Patient selection bias (Cohorts) Low risk Assignmentwas based on catchment areas (in-
tervention clinics / control clinics)
Jaffar 2009
Methods Design: Cluster randomised controlled trial, 22 clusters for each arm, median size 25 - 36,
inter-cluster co-efficient 0.2
Duration: February 2005 -December 2006, follow-up until 31 January 2009,median follow-
up 27 - 28 months
Participants Country: Uganda
Setting: Urban, peri-urban and rural, varying distance from the hospital
Inclusion criteria: Adults >18 years old, CD4+ cell count <200cells/mm3, WHO clinical
stage 3 or 4
Exclusion criteria: Living >100 km from facility
Comparable CD4+ cell count or clinical stage at baseline: Similar, slightly lower CD4+ cell
count for intervention arm
Interventions Intervention: ART initiated at hospital by doctors, maintained in the community by field
officers who delivered treatments every month on motorcycles, monitored adherence, drug
toxicity and disease, they referred patients; had access to mobile phones for on-site call to
doctor. If patients was absent, followed up. Reviewed at hospital 6 monthly
Control: ART initiated and maintained at hospital. Monthly clinic visits to collect medicine,
reviewed by medical officer 3 monthly, drop in clinic; if defaulted, followed up at home;
household vouchers for counselling
Outcomes Rate of virological failure, time to detectable viral load >500 copies/mL, time to detectable
viral load >500 copies/mL at any visit from 12 months if it was <500 copies/mL at 6 months
or increase in 1000 copies/mL between two consecutive tests in those who did not have
viral load <500 copies/mL at 6 months, all cause mortality, admission, change to second line
antiretrovirals, outpatient attendance, adherence in previous 28 days, cost incurred by health
services and patients, patient diagnosed with TB at first admission, proportion of those with
CD4+ cell count > 200cells/mm3
Timepoints of outcome assessment not clear
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Baseline CD4 count (All studies) Low risk Similar at baseline
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Jaffar 2009 (Continued)
Other baseline variables (All studies) Low risk Comparable baseline characteristics
Co-interventions (All studies) Low risk Both groups seen monthly, but provider and
facility differed by group
Random sequence generation (Trials) Unclear risk Not described
Allocation concealment (Trials) Low risk Allocation cards labelled with stratum num-
ber and sealed in advance was drawn from
a concealed box in the presence of all stake-
holders
Contamination protection (Trials) Low risk No evidence of contamination
Kipp 2010
Methods Design: Prospective cohort
Duration: 6 month results
Participants Country: Rwimi, Uganda
Setting: intervention in rural setting, control in urban setting
Inclusion criteria: Adults >18 years, eligible for antiretroviral therapy, antiretroviral therapy
naive, resident in the sub-county
Exclusion criteria: None described
Comparable CD4 count or clinical stage at baseline: Similar CD4+ cell count at baseline
Interventions Intervention: ART initiated at the health centre, maintained in community receiving care
from volunteer community health workers who did weekly home visits - delivering antiretro-
virals monthly, monitoring and supporting adherence, monitoring adverse effects and clinical
symptoms
Control: ART initiated and maintained in hospital, by doctors
Co-intervention: an additional treatment support was required by those in the home-based
group to support adherence and disclosure
Outcomes Mortality, viral load, increase in CD4+ cell count, cost to provider
Assessed at 6 months and 24 months
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Baseline CD4 count (All studies) Low risk Similar mean CD4+ cell count in both groups
Other baseline variables (All studies) Low risk Age, sex and educational status similar at base-
line (although occupations different).,
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Kipp 2010 (Continued)
Co-interventions (All studies) High risk Treatment supporter was required by home-
based care group
Data collection (Cohorts) Low risk Prospective cohort
Patient selection bias (Cohorts) Low risk No selection bias identified
Massaquoi 2009
Methods Design: Retrospective cohort
Duration: 1 June 2006 - 31 June 2007, censored 31 June 2007
Participants Country: Thyolo District, Malawi
Setting: Rural, 1 hospital, 9 health centres
Inclusion criteria: HIV infected adults and children, eligible for antiretrovirals, CD4 count
<250cells/mm3, WHO clinical stage 3 or 4
Exclusion criteria: None described
Comparable CD4 count or clinical stage at baseline: More men and children and stage 4
disease at hospital, more patients with active tuberculosis at the health centre
Interventions Intervention: ART initiated and maintained at health centre, by medical assistant, 1 nurse
Control: ART initiated andmaintained at hospital by clinical officer,medical assistants, nurses,
counsellors
Co-interventions: Both have district mobile support teams
Outcomes Attrition (dead, loss to follow-up, stopped treatment), retention (alive and on treatment, and
transferred out)
Assessment of outcomes provided in person-years of follow-up
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Baseline CD4 count (All studies) Unclear risk Not reported
Other baseline variables (All studies) High risk Sicker at peripheral site: More men and chil-
dren,WHO clinical stage 4 disease, and fewer
patients with active Tuberculosis at control
site
Co-interventions (All studies) Unclear risk The community-based
group received monthly visits from volunteer
community support providers, and delivery
of their medicines. They were also required to
identify a treatment supporter at home, not
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Massaquoi 2009 (Continued)
clear if this applied to both groups
Data collection (Cohorts) High risk Retrospective cohort
Patient selection bias (Cohorts) Low risk No selection bias identified
McGuire 2012
Methods Design: Retrospective cohort
Duration: August 2001 to December 2008, compared by year (e.g. 2001/2002; 2003/2004
etc)
Participants Country: Malawi
Setting: 10 peripheral health centres, 1 district hospital
Inclusion criteria: HIV infected adults, eligible for antiretrovirals, CD4 count <250cells/mm
3, WHO clinical stage 3 or 4
Exclusion criteria: None described
Comparable CD4 count or clinical stage at baseline: CD4+ cell count similar at baseline
median IQR 176 cells/mm3 [105 -229] at the health centre and 149 cells/mm3 [74 - 219];
however more clinical stage 1 and 2 at the health centre which may favour the intervention,
also more men at the hospital
Interventions Intervention: ART initiated and maintained at health centre, by clinical officers. Medical
assistants and nurses could prescribe after 2007
Control: ART initiated andmaintained at hospital by clinical officer,medical assistants, nurses
Co-interventions: Lay community workers, peer counsellors for adherence support, group
and individual counselling
Outcomes Death, loss to follow-up and attrition (death and loss to follow-up) at 12 months
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Baseline CD4 count (All studies) High risk Healthier at peripheral site: CD4+ cell count
higher.
Other baseline variables (All studies) High risk Healthier at peripheral site: (clinical stage 1
and 2).
Co-interventions (All studies) Low risk default tracing by community health workers,
seems to be same for both facilities
Data collection (Cohorts) High risk Retrospective cohort
Patient selection bias (Cohorts) Low risk No evidence of selection bias
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Odafe 2012
Methods Design: Retrospective cohort
Duration:Initiated therapy between January and December 2007, follow-up data collected
until 2010
Participants Country: Nigeria
Setting: Secondary (medical officers, nurses, laboratory scientists, pharmacists and community
heath officers) and tertiary hospitals (medical specialists) in Nigeria where majority of ART
initiation occurs
Inclusion criteria: HIV infected adults and children, eligible for antiretrovirals by Nigeria
national recommendations, adapted from WHO recommendations
Exclusion criteria: None described
Comparable CD4 count or clinical stage at baseline: CD4+ cell count not reported, but more
patients with clinical stage 3 and 4 at the hospital
Interventions Intervention: ART initiated and maintained at health centre, by clinical officers. Medical
assistants and nurses could prescribe after 2007
Control: ART initiated andmaintained at hospital by clinical officer,medical assistants, nurses
Co-interventions: Adehrence counselling and pharmacy counselling received at every visit, at
both tiers of health service
Outcomes Primary outcome was attrition, which includes those stopping treatment,confirmed dead or
lost to follow-up at 12 and 24 months. Loss to follow-up was defined as those absent from
treatment for 90 days
Notes As this comparison included tertiary vs secondary hospitals, this differed from other models
in the analysis and is therefore described narratively, not included in analysis
Risk of bias
Bias Authors’ judgement Support for judgement
Baseline CD4 count (All studies) Unclear risk Not stated
Other baseline variables (All studies) High risk More patients withWHO clinical stage 3 dis-
ease at the secondary hospital, this is likely to
increase bias in favour of control
Co-interventions (All studies) Low risk Same approach to adherence support and
counselling in both settings
Data collection (Cohorts) High risk Retrospecrive cohort
Patient selection bias (Cohorts) Low risk No selection bias identified
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Selke 2010
Methods Design: Cluster randomised controlled trial. Unit of allocation: sub-location, stratified by
distance from road, inter cluster co-efficient not found
Duration: March 2006 - April 2008, minimum 12 months follow-up
Participants Country: Kenya
Setting: Rural, 24 sub-locations
Inclusion criteria: adults >18 years, clinically stable on antiretroviral therapy for 3 months
with no adherence issues, disclosed to householdmembers, live within area, informed consent
given
Exclusion criteria: Active WHO clinical stage 3 or 4 condition, pregnant, hospitalisation in
previous 3 months, unable to understand informed consent process
Comparable CD4 count or clinical stage at baseline:similar CD4+ cell count and WHO
clinical stage
Interventions Intervention: ART initiated at hospital by clinical officer,maintained in community by person
living with HIV/AIDS (“community care coordinators” who had secondary education, were
clinically stable, 100% adherent and “considered a good role model”; trained, given mobile
computer decision aids, visited patients monthly at home and delivered medicines. Three
monthly clinic visits seen by doctor or clinical officer
Control: ART initiated at hospital by clinical officer or doctor (10% of visits), maintained at
hospital. Visit clinic monthly, seen by nurse and doctor
Co-interventions: community coordinators had computer decision aids to trigger referral for
clinical or social concerns
Outcomes Viral load, CD4+ cell count, number of clinic visits, Karnofsky score, stability of antiretroviral
regimen, opportunistic infections, pregnancy, adherence to drugs, loss to follow-up
Assessed at 12 months
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Baseline CD4 count (All studies) Low risk Similar at baseline
Other baseline variables (All studies) Low risk Similar baseline characteristics including age,
sex and WHO clinical staging
Co-interventions (All studies) Low risk Other than the intervention (computerised
decision aids and home-based support) the
groups were treated equally
Random sequence generation (Trials) Unclear risk Not clearly described
Allocation concealment (Trials) Low risk Well described
Contamination protection (Trials) Low risk Unlikely that control group was exposed to
intervention
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Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Babigumira 2009 Decision analysis model using one patient as case study.
Bemelmans 2010 Description of program outcomes.
Bolton-Moore 2007 No contemporaneous comparison group.
Boyer 2010 Cross-sectional survey.
Boyer 2012 Cross-sectional survey.
Chu 2010 Randomised controlled trial conducted in high income country (United States of America)
Cohen 2009 No contemporaneous comparison group.
Ingle 2010 Cohort study with no clear comparison between standard level/model of care and a decentralised model
Lambdin 2013 Intervention being evaluated was integration of care vs vertical care, both occurred at primary care setting
Leon 2011 Randomised controlled trial done in high income country (Spain)
Shumbusho 2009 Cohort (task shifting) with no comparison group.
Stein 2007 Qualitative data from health care workers only.
Tene 2013 Cohort study with no clear comparison between standard level/model of care and a decentralised model
Characteristics of studies awaiting assessment [ordered by study ID]
Assefa 2012b
Methods
Participants
Interventions
Outcomes
Notes Presentation at International AIDS Conference, 2012. Awaiting additional information from authors. Querying
whether this a sub-study within Assefa 2012 or a different population.
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Labhart 2012
Methods Data from International epidemiologic databases to evaluate AIDS in Southern Africa network (IeDEA-SA). Pro-
grammatic data
Participants 9 Hospitals and 40 health centres in 4 countries, 13 100 patients on ART in 2011
Inclusion criteria: >16 years old at start of ART, no previous ART exposure
Baseline characteristics well balanced for sex and age, but not for CD4+ cell counts which were lower at hospital and
WHO clinical stages which were more advanced at the hospitals
Decentralisation model currently underway in Lesotho
Interventions ART received at nurse run health centres
Outcomes Loss to follow-up defined as not returning to clinic >= 6 months, mortality
Notes Oral presentation at the International AIDS Conference, 2012. Additional data regarding loss to follow-up needed
Miyano 2012
Methods
Participants
Interventions
Outcomes
Notes Presentation at International AIDS Conference, 2012. Seeking additional information about publication of this data
to assess eligibility
Morsheimer (unpublished)
Methods Retrospective cohort
Participants Children eligible for antiretroviral therapy in South Africa
Interventions Initiation and maintenance by paediatric medical officers in health centres (enhanced) compared to initiation at an
advanced hospital by paediatric doctors and down referral to health centres
Outcomes Mortality, retention, CD4 count
Notes Awaiting feedback from author about outcomes of interest
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Van Dijk 2012
Methods Cohort study in children
Before and after results of decentralisation from hospital to ’outreach’ site
Participants Children in paediatric cohort in rural Zambia
Interventions Decentralisation to outreach site, not clear when initiation of ART occurred
Outcomes Cost, travel time, death, loss to follow-up, viral load
Notes Oral presentation at the International AIDS Conference, 2012. Concludes that outreach group less likely to achieve
virological suppression, but travel costs and times lower. Need additional information from authors regarding study
design and whether the arms of the study were evaluated contemporaneously
Characteristics of ongoing studies [ordered by study ID]
NCT 01414413
Trial name or title Home assessment and initiation of ART: a cluster-randomised controlled trial in Blantyre, Malawi
Methods Randomised open-label parallel arm trial
Participants Adults >18 years of age, HIV positive and eligible for ART
Interventions Intervention: Home assessment and initiation of ART
Control: Clinic-based ART assessment and initiation
Outcomes Primary outcome: Antiretroviral initiation within first 6 months
Secondary outcomes: Uptake of home-based HIV testing, disclosure of HIV results, retention on ART,
adherence to ART, mortality
Starting date January 2012
Contact information Peter MacPherson, p.macpherson@liverpool.ac.za
Notes
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D A T A A N D A N A L Y S E S
Comparison 1. Partial decentralisation - initiation in hospital, maintenance at health centre
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Death or lost to care (12 months) 4 39090 Risk Ratio (IV, Random, 95% CI) 0.46 [0.29, 0.71]
1.1 Adults 2 29492 Risk Ratio (IV, Random, 95% CI) 0.49 [0.21, 1.12]
1.2 Children 1 1505 Risk Ratio (IV, Random, 95% CI) 0.45 [0.27, 0.74]
1.3 Adults and children 1 8093 Risk Ratio (IV, Random, 95% CI) 0.39 [0.35, 0.43]
2 Lost to care 6 Risk Ratio (IV, Random, 95% CI) Subtotals only
2.1 Lost to care (6 months) 3 28699 Risk Ratio (IV, Random, 95% CI) 0.99 [0.56, 1.76]
2.2 Lost to care (12 months) 4 39090 Risk Ratio (IV, Random, 95% CI) 0.55 [0.45, 0.69]
2.3 Lost to care (24 months) 1 543 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
3 Death 6 Risk Ratio (IV, Random, 95% CI) Subtotals only
3.1 Death (6 months) 3 28699 Risk Ratio (IV, Random, 95% CI) 0.52 [0.19, 1.41]
3.2 Death (12 months) 4 39090 Risk Ratio (IV, Random, 95% CI) 0.34 [0.13, 0.87]
3.3 Death (24 months) 1 543 Risk Ratio (IV, Random, 95% CI) 0.04 [0.00, 0.58]
4 Cost of travel Other data No numeric data
4.1 cost of travel Other data No numeric data
Comparison 2. Full decentralisation - initiation and maintenance in health centre
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Death or lost to care (12 months) 4 56360 Risk Ratio (IV, Random, 95% CI) 0.70 [0.47, 1.02]
1.1 Adults 3 52286 Risk Ratio (IV, Random, 95% CI) 0.62 [0.39, 0.99]
1.2 Adults and children 1 4074 Risk Ratio (IV, Random, 95% CI) 0.97 [0.82, 1.15]
2 Lost to care 6 Risk Ratio (IV, Random, 95% CI) Subtotals only
2.1 Lost to care (6 months) 2 51261 Risk Ratio (IV, Random, 95% CI) 0.53 [0.26, 1.10]
2.2 Lost to care (12 months) 4 56360 Risk Ratio (IV, Random, 95% CI) 0.30 [0.17, 0.54]
2.3 Lost to care (24 months) 4 61445 Risk Ratio (IV, Random, 95% CI) 0.50 [0.36, 0.71]
3 Death 6 Risk Ratio (IV, Random, 95% CI) Subtotals only
3.1 Death (6 months) 2 50000 Risk Ratio (IV, Random, 95% CI) 0.84 [0.35, 2.00]
3.2 Death (12 Months) 4 55099 Risk Ratio (IV, Random, 95% CI) 1.10 [0.63, 1.92]
3.3 Death (24 months) 4 60184 Risk Ratio (IV, Random, 95% CI) 0.64 [0.39, 1.06]
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Comparison 3. Decentralisation - from the facility to the community for antiretroviral maintenance therapy
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Death or lost to care (12 months) 2 709 Risk Ratio (IV, Random, 95% CI) 0.95 [0.62, 1.46]
2 Lost to care 3 Risk Ratio (IV, Random, 95% CI) Subtotals only
2.1 Lost to care (6 months) 1 385 Risk Ratio (IV, Random, 95% CI) 1.49 [0.81, 2.74]
2.2 Lost to care (12 months) 2 709 Risk Ratio (IV, Random, 95% CI) 0.81 [0.30, 2.21]
2.3 Lost to care (24 months) 1 385 Risk Ratio (IV, Random, 95% CI) 0.74 [0.46, 1.20]
3 Death 3 Risk Ratio (IV, Random, 95% CI) Subtotals only
3.1 Death (6 months) 1 385 Risk Ratio (IV, Random, 95% CI) 1.44 [0.81, 2.57]
3.2 Death (12 months) 2 709 Risk Ratio (IV, Random, 95% CI) 1.03 [0.64, 1.65]
3.3 Death (24 months) 1 385 Risk Ratio (IV, Random, 95% CI) 1.50 [0.91, 2.47]
4 Cost to patient Other data No numeric data
Analysis 1.1. Comparison 1 Partial decentralisation - initiation in hospital, maintenance at health centre,
Outcome 1 Death or lost to care (12 months).
Review: Decentralising HIV treatment in lower- and middle-income countries
Comparison: 1 Partial decentralisation - initiation in hospital, maintenance at health centre
Outcome: 1 Death or lost to care (12 months)
Study or subgroup Decentralisation Hospital care Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
1 Adults
Brennan 2011 12/693 119/2079 19.6 % 0.30 [ 0.17, 0.54 ]
Fatti 2010 3448/19273 1875/7447 29.5 % 0.71 [ 0.68, 0.75 ]
Subtotal (95% CI) 19966 9526 49.1 % 0.49 [ 0.21, 1.12 ]
Total events: 3460 (Decentralisation), 1994 (Hospital care)
Heterogeneity: Tau2 = 0.32; Chi2 = 8.06, df = 1 (P = 0.005); I2 =88%
Test for overall effect: Z = 1.69 (P = 0.091)
2 Children
Bock 2008 17/361 120/1144 21.8 % 0.45 [ 0.27, 0.74 ]
Subtotal (95% CI) 361 1144 21.8 % 0.45 [ 0.27, 0.74 ]
Total events: 17 (Decentralisation), 120 (Hospital care)
Heterogeneity: not applicable
Test for overall effect: Z = 3.18 (P = 0.0015)
3 Adults and children
Chan 2010 352/3440 1223/4653 29.1 % 0.39 [ 0.35, 0.43 ]
0.01 0.1 1 10 100
Decentralisation Hospital care
(Continued . . . )
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(. . . Continued)
Study or subgroup Decentralisation Hospital care Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Subtotal (95% CI) 3440 4653 29.1 % 0.39 [ 0.35, 0.43 ]
Total events: 352 (Decentralisation), 1223 (Hospital care)
Heterogeneity: not applicable
Test for overall effect: Z = 16.80 (P < 0.00001)
Total (95% CI) 23767 15323 100.0 % 0.46 [ 0.29, 0.71 ]
Total events: 3829 (Decentralisation), 3337 (Hospital care)
Heterogeneity: Tau2 = 0.18; Chi2 = 103.74, df = 3 (P<0.00001); I2 =97%
Test for overall effect: Z = 3.44 (P = 0.00059)
Test for subgroup differences: Chi2 = 0.57, df = 2 (P = 0.75), I2 =0.0%
0.01 0.1 1 10 100
Decentralisation Hospital care
Analysis 1.2. Comparison 1 Partial decentralisation - initiation in hospital, maintenance at health centre,
Outcome 2 Lost to care.
Review: Decentralising HIV treatment in lower- and middle-income countries
Comparison: 1 Partial decentralisation - initiation in hospital, maintenance at health centre
Outcome: 2 Lost to care
Study or subgroup Decentralisation Hospital care Risk Ratio Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
1 Lost to care (6 months)
Bock 2008 (1) 11/361 28/1144 1.24 [ 0.63, 2.48 ]
Fatti 2010 1033/19273 553/7447 0.72 [ 0.65, 0.80 ]
Humphreys 2010 10/317 2/157 2.48 [ 0.55, 11.17 ]
Subtotal (95% CI) 19951 8748 0.99 [ 0.56, 1.76 ]
Total events: 1054 (Decentralisation), 583 (Hospital care)
Heterogeneity: Tau2 = 0.15; Chi2 = 4.88, df = 2 (P = 0.09); I2 =59%
Test for overall effect: Z = 0.03 (P = 0.97)
2 Lost to care (12 months)
Bock 2008 (2) 11/361 37/1144 0.94 [ 0.49, 1.83 ]
Brennan 2011 10/693 87/2079 0.34 [ 0.18, 0.66 ]
0.01 0.1 1 10 100
Decentralisation Hospital care
(Continued . . . )
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(. . . Continued)
Study or subgroup Decentralisation Hospital care Risk Ratio Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Chan 2010 253/3440 698/4653 0.49 [ 0.43, 0.56 ]
Fatti 2010 1955/19273 1233/7447 0.61 [ 0.57, 0.65 ]
Subtotal (95% CI) 23767 15323 0.55 [ 0.45, 0.69 ]
Total events: 2229 (Decentralisation), 2055 (Hospital care)
Heterogeneity: Tau2 = 0.03; Chi2 = 12.80, df = 3 (P = 0.01); I2 =77%
Test for overall effect: Z = 5.32 (P < 0.00001)
3 Lost to care (24 months)
Hansudewechakul 2012 (3) 0/133 0/410 0.0 [ 0.0, 0.0 ]
Subtotal (95% CI) 133 410 0.0 [ 0.0, 0.0 ]
Total events: 0 (Decentralisation), 0 (Hospital care)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
0.01 0.1 1 10 100
Decentralisation Hospital care
(1) Study in children
(2) Study in children
(3) Study in children
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Analysis 1.3. Comparison 1 Partial decentralisation - initiation in hospital, maintenance at health centre,
Outcome 3 Death.
Review: Decentralising HIV treatment in lower- and middle-income countries
Comparison: 1 Partial decentralisation - initiation in hospital, maintenance at health centre
Outcome: 3 Death
Study or subgroup Decentralisation Hospital care Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
1 Death (6 months)
Bock 2008 (1) 6/361 77/1144 33.4 % 0.25 [ 0.11, 0.56 ]
Fatti 2010 777/19273 314/7447 42.9 % 0.96 [ 0.84, 1.09 ]
Humphreys 2010 4/317 4/157 23.7 % 0.50 [ 0.13, 1.95 ]
Subtotal (95% CI) 19951 8748 100.0 % 0.52 [ 0.19, 1.41 ]
Total events: 787 (Decentralisation), 395 (Hospital care)
Heterogeneity: Tau2 = 0.60; Chi2 = 10.96, df = 2 (P = 0.004); I2 =82%
Test for overall effect: Z = 1.29 (P = 0.20)
2 Death (12 months)
Bock 2008 6/361 83/1144 24.1 % 0.23 [ 0.10, 0.52 ]
Brennan 2011 2/693 32/2079 17.5 % 0.19 [ 0.05, 0.78 ]
Chan 2010 99/3440 525/4653 29.0 % 0.26 [ 0.21, 0.31 ]
Fatti 2010 1493/19273 642/7447 29.4 % 0.90 [ 0.82, 0.98 ]
Subtotal (95% CI) 23767 15323 100.0 % 0.34 [ 0.13, 0.87 ]
Total events: 1600 (Decentralisation), 1282 (Hospital care)
Heterogeneity: Tau2 = 0.78; Chi2 = 128.46, df = 3 (P<0.00001); I2 =98%
Test for overall effect: Z = 2.25 (P = 0.025)
3 Death (24 months)
Hansudewechakul 2012 (2) 0/133 42/410 100.0 % 0.04 [ 0.00, 0.58 ]
Subtotal (95% CI) 133 410 100.0 % 0.04 [ 0.00, 0.58 ]
Total events: 0 (Decentralisation), 42 (Hospital care)
Heterogeneity: not applicable
Test for overall effect: Z = 2.34 (P = 0.019)
0.01 0.1 1 10 100
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(1) Study in children
(2) Study in children
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Analysis 1.4. Comparison 1 Partial decentralisation - initiation in hospital, maintenance at health centre,
Outcome 4 Cost of travel.
Cost of travel
Study Down referred patient Hospital care patient P-value
cost of travel
Humphreys 2010 Average cost for follow up care USD
0.74
Average cost for follow up care USD
1.5
P = 0.001
Analysis 2.1. Comparison 2 Full decentralisation - initiation and maintenance in health centre, Outcome 1
Death or lost to care (12 months).
Review: Decentralising HIV treatment in lower- and middle-income countries
Comparison: 2 Full decentralisation - initiation and maintenance in health centre
Outcome: 1 Death or lost to care (12 months)
Study or subgroup Decentralisation Hospital care Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
1 Adults
Bedelu 2007 113/595 141/430 23.9 % 0.58 [ 0.47, 0.72 ]
McGuire 2012 1509/9782 1082/3344 25.6 % 0.48 [ 0.45, 0.51 ]
Assefa 2012 2105/6206 12450/31929 25.8 % 0.87 [ 0.84, 0.90 ]
Subtotal (95% CI) 16583 35703 75.3 % 0.62 [ 0.39, 0.99 ]
Total events: 3727 (Decentralisation), 13673 (Hospital care)
Heterogeneity: Tau2 = 0.17; Chi2 = 239.29, df = 2 (P<0.00001); I2 =99%
Test for overall effect: Z = 1.98 (P = 0.047)
2 Adults and children
Massaquoi 2009 168/1170 429/2904 24.7 % 0.97 [ 0.82, 1.15 ]
Subtotal (95% CI) 1170 2904 24.7 % 0.97 [ 0.82, 1.15 ]
Total events: 168 (Decentralisation), 429 (Hospital care)
Heterogeneity: not applicable
Test for overall effect: Z = 0.34 (P = 0.74)
Total (95% CI) 17753 38607 100.0 % 0.70 [ 0.47, 1.02 ]
Total events: 3895 (Decentralisation), 14102 (Hospital care)
Heterogeneity: Tau2 = 0.15; Chi2 = 248.34, df = 3 (P<0.00001); I2 =99%
Test for overall effect: Z = 1.85 (P = 0.064)
Test for subgroup differences: Chi2 = 3.09, df = 1 (P = 0.08), I2 =68%
0.2 0.5 1 2 5
Decentralisation Hospital care
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Analysis 2.2. Comparison 2 Full decentralisation - initiation and maintenance in health centre, Outcome 2
Lost to care.
Review: Decentralising HIV treatment in lower- and middle-income countries
Comparison: 2 Full decentralisation - initiation and maintenance in health centre
Outcome: 2 Lost to care
Study or subgroup Decentralisation Hospital care Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
1 Lost to care (6 months)
Assefa 2012 741/6206 4935/31929 50.2 % 0.77 [ 0.72, 0.83 ]
McGuire 2012 486/9782 451/3344 49.8 % 0.37 [ 0.33, 0.42 ]
Subtotal (95% CI) 15988 35273 100.0 % 0.53 [ 0.26, 1.10 ]
Total events: 1227 (Decentralisation), 5386 (Hospital care)
Heterogeneity: Tau2 = 0.27; Chi2 = 104.79, df = 1 (P<0.00001); I2 =99%
Test for overall effect: Z = 1.69 (P = 0.091)
2 Lost to care (12 months)
Assefa 2012 1407/6206 9535/31929 27.4 % 0.76 [ 0.72, 0.80 ]
Bedelu 2007 13/595 83/430 21.9 % 0.11 [ 0.06, 0.20 ]
Massaquoi 2009 18/1170 227/2904 23.4 % 0.20 [ 0.12, 0.32 ]
McGuire 2012 632/9782 584/3344 27.3 % 0.37 [ 0.33, 0.41 ]
Subtotal (95% CI) 17753 38607 100.0 % 0.30 [ 0.17, 0.54 ]
Total events: 2070 (Decentralisation), 10429 (Hospital care)
Heterogeneity: Tau2 = 0.33; Chi2 = 208.63, df = 3 (P<0.00001); I2 =99%
Test for overall effect: Z = 3.98 (P = 0.000069)
3 Lost to care (24 months)
Assefa 2012 1517/6206 11188/31929 27.0 % 0.70 [ 0.67, 0.73 ]
Balcha 2010 24/252 331/1457 20.1 % 0.42 [ 0.28, 0.62 ]
Fayorsey 2013 (1) 282/2443 1274/6032 26.3 % 0.55 [ 0.48, 0.62 ]
McGuire 2012 840/9782 743/3344 26.6 % 0.39 [ 0.35, 0.42 ]
Subtotal (95% CI) 18683 42762 100.0 % 0.50 [ 0.36, 0.71 ]
Total events: 2663 (Decentralisation), 13536 (Hospital care)
Heterogeneity: Tau2 = 0.11; Chi2 = 136.61, df = 3 (P<0.00001); I2 =98%
Test for overall effect: Z = 3.90 (P = 0.000096)
0.1 0.2 0.5 1 2 5 10
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Analysis 2.3. Comparison 2 Full decentralisation - initiation and maintenance in health centre, Outcome 3
Death.
Review: Decentralising HIV treatment in lower- and middle-income countries
Comparison: 2 Full decentralisation - initiation and maintenance in health centre
Outcome: 3 Death
Study or subgroup Decentralisation Hospital care Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
1 Death (6 months)
Assefa 2012 384/6206 1513/31929 50.0 % 1.31 [ 1.17, 1.46 ]
McGuire 2012 727/9094 411/2771 50.0 % 0.54 [ 0.48, 0.60 ]
Subtotal (95% CI) 15300 34700 100.0 % 0.84 [ 0.35, 2.00 ]
Total events: 1111 (Decentralisation), 1924 (Hospital care)
Heterogeneity: Tau2 = 0.39; Chi2 = 122.14, df = 1 (P<0.00001); I2 =99%
Test for overall effect: Z = 0.40 (P = 0.69)
2 Death (12 Months)
Assefa 2012 698/6206 2915/31929 25.6 % 1.23 [ 1.14, 1.33 ]
Bedelu 2007 100/595 58/430 24.0 % 1.25 [ 0.92, 1.68 ]
Massaquoi 2009 150/1170 202/2904 24.9 % 1.84 [ 1.51, 2.25 ]
McGuire 2012 877/9094 498/2771 25.5 % 0.54 [ 0.48, 0.59 ]
Subtotal (95% CI) 17065 38034 100.0 % 1.10 [ 0.63, 1.92 ]
Total events: 1825 (Decentralisation), 3673 (Hospital care)
Heterogeneity: Tau2 = 0.31; Chi2 = 209.25, df = 3 (P<0.00001); I2 =99%
Test for overall effect: Z = 0.35 (P = 0.72)
3 Death (24 months)
Assefa 2012 794/6206 3438/31929 27.0 % 1.19 [ 1.11, 1.28 ]
Balcha 2010 11/252 164/1457 19.7 % 0.39 [ 0.21, 0.70 ]
Fayorsey 2013 (1) 151/2443 674/6032 26.4 % 0.55 [ 0.47, 0.66 ]
McGuire 2012 1052/9094 563/2771 26.9 % 0.57 [ 0.52, 0.62 ]
Subtotal (95% CI) 17995 42189 100.0 % 0.64 [ 0.39, 1.06 ]
Total events: 2008 (Decentralisation), 4839 (Hospital care)
Heterogeneity: Tau2 = 0.24; Chi2 = 184.97, df = 3 (P<0.00001); I2 =98%
Test for overall effect: Z = 1.74 (P = 0.081)
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Analysis 3.1. Comparison 3 Decentralisation - from the facility to the community for antiretroviral
maintenance therapy, Outcome 1 Death or lost to care (12 months).
Review: Decentralising HIV treatment in lower- and middle-income countries
Comparison: 3 Decentralisation - from the facility to the community for antiretroviral maintenance therapy
Outcome: 1 Death or lost to care (12 months)
Study or subgroup Community care Facility care Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Jaffar 2009 (1) 39/330 29/229 90.0 % 0.93 [ 0.60, 1.46 ]
Selke 2010 (2) 4/69 4/81 10.0 % 1.17 [ 0.30, 4.52 ]
Total (95% CI) 399 310 100.0 % 0.95 [ 0.62, 1.46 ]
Total events: 43 (Community care), 33 (Facility care)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.10, df = 1 (P = 0.75); I2 =0.0%
Test for overall effect: Z = 0.21 (P = 0.83)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Community care Facility care
(1) We assumed an ICC of 0.05 as none was provided in the trial report.
(2) We assumed an ICC of 0.05 as none was provided in the trial report
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Analysis 3.2. Comparison 3 Decentralisation - from the facility to the community for antiretroviral
maintenance therapy, Outcome 2 Lost to care.
Review: Decentralising HIV treatment in lower- and middle-income countries
Comparison: 3 Decentralisation - from the facility to the community for antiretroviral maintenance therapy
Outcome: 2 Lost to care
Study or subgroup Community care Facility care Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
1 Lost to care (6 months)
Kipp 2010 22/185 16/200 100.0 % 1.49 [ 0.81, 2.74 ]
Subtotal (95% CI) 185 200 100.0 % 1.49 [ 0.81, 2.74 ]
Total events: 22 (Community care), 16 (Facility care)
Heterogeneity: not applicable
Test for overall effect: Z = 1.27 (P = 0.20)
2 Lost to care (12 months)
Jaffar 2009 3/330 4/229 45.1 % 0.52 [ 0.12, 2.30 ]
Selke 2010 4/69 4/81 54.9 % 1.17 [ 0.30, 4.52 ]
Subtotal (95% CI) 399 310 100.0 % 0.81 [ 0.30, 2.21 ]
Total events: 7 (Community care), 8 (Facility care)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.63, df = 1 (P = 0.43); I2 =0.0%
Test for overall effect: Z = 0.41 (P = 0.69)
3 Lost to care (24 months)
Kipp 2010 24/185 35/200 100.0 % 0.74 [ 0.46, 1.20 ]
Subtotal (95% CI) 185 200 100.0 % 0.74 [ 0.46, 1.20 ]
Total events: 24 (Community care), 35 (Facility care)
Heterogeneity: not applicable
Test for overall effect: Z = 1.22 (P = 0.22)
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Analysis 3.3. Comparison 3 Decentralisation - from the facility to the community for antiretroviral
maintenance therapy, Outcome 3 Death.
Review: Decentralising HIV treatment in lower- and middle-income countries
Comparison: 3 Decentralisation - from the facility to the community for antiretroviral maintenance therapy
Outcome: 3 Death
Study or subgroup Community care Facility care Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
1 Death (6 months)
Kipp 2010 24/185 18/200 100.0 % 1.44 [ 0.81, 2.57 ]
Subtotal (95% CI) 185 200 100.0 % 1.44 [ 0.81, 2.57 ]
Total events: 24 (Community care), 18 (Facility care)
Heterogeneity: not applicable
Test for overall effect: Z = 1.24 (P = 0.21)
2 Death (12 months)
Jaffar 2009 36/330 25/229 97.8 % 1.00 [ 0.62, 1.62 ]
Selke 2010 1/69 0/81 2.2 % 3.51 [ 0.15, 84.90 ]
Subtotal (95% CI) 399 310 100.0 % 1.03 [ 0.64, 1.65 ]
Total events: 37 (Community care), 25 (Facility care)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.59, df = 1 (P = 0.44); I2 =0.0%
Test for overall effect: Z = 0.11 (P = 0.91)
3 Death (24 months)
Kipp 2010 32/185 23/200 100.0 % 1.50 [ 0.91, 2.47 ]
Subtotal (95% CI) 185 200 100.0 % 1.50 [ 0.91, 2.47 ]
Total events: 32 (Community care), 23 (Facility care)
Heterogeneity: not applicable
Test for overall effect: Z = 1.61 (P = 0.11)
0.01 0.1 1 10 100
Community care Facility care
Analysis 3.4. Comparison 3 Decentralisation - from the facility to the community for antiretroviral
maintenance therapy, Outcome 4 Cost to patient.
Cost to patient
Study Home based care Hospital based care
Jaffar 2009 total cost per year for transport, lunch, childcare costs, lost
work time: $18/year (after first year)
total cost per year for transport, lunch, childcare costs, lost
work time: $54/ year (after the first year)
Kipp 2010 Transport cost $0.74/ visit for home based care Transport cost $1.5/ visit for facility based care
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A D D I T I O N A L T A B L E S
Table 1. Health service nomenclature in lower- and middle-income countries
Tier Highest cadre Terms often used Facility and staff Equipment facilities
Community Individual with maxi-
mum of few months
training; paid or unpaid
1a. Family led care Family member
1b. Village volunteer Trained volunteer;
health assistants
HIV tests, counselling,
replenish drugs
1c. Primary care clinic Nurse aide or commu-
nity health worker with a
few months training
Health centre clinical officer or nurse
(2+ years training)
Health centres; district
hospitals
Purpose built with at
least one paramedic or
nurse with some health
assistants
HIV tests; antiretrovi-
rals; opportunistic infec-
tions medicines; point of
care laboratories
Health centre
(enhanced)
Clinical officer or nurse
(2 + years training)
Health centres, primary
healthcare clinics, dis-
trict hospitals
Purpose built with at
least one paramedic or
nurse with some health
assistants, with input
from a doctor (may be
via mobile support ser-
vice)
HIV tests; antiretrovi-
rals; opportunistic infec-
tions medicines; point of
care laboratories
Hospital Doctor Health centres; district
hospitals
Purpose built with at
least one medical doctor
with nurses / paramedics
and assistants
CD4 count
Medicines
Not viral load
Hospital (advanced) Specialist doctor District hospital; referral
hospital
Purpose built with at
least 2 specialist doctors
with nurses / paramedics
and assistants
Viral load and full inves-
tigations
Table 2. Models of HIV care
Our term Initiation Follow-up
Standard hospital model Hospital Hospital
Partial decentralisation Hospital Health centre
Full decentralisation Health centre Health centre
Full decentralisation with regular hospital
support
Health centre (weekly clinics with hospital
staff )
Health centre (weekly clinics with hospital
staff )
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Table 2. Models of HIV care (Continued)
Community Primary (tier 1c)
Health centre
Primary (tier 1c)
(monitor six monthly by health centre)
Table 3. Description of the models of care of included studies
Models of care Provider de-
tails
Laboratory
facilities
Community
support
Train-
ing in ART
initiation and
maintenance
Supervision
or mentoring
Referral
Partial decentralisation
Bock 2008 Health centres
(enhanced)
Doctors yes not stated not stated specialists
available
yes
Hospital (ad-
vanced)
Doctors yes not stated yes specialists
available
not applicable
Brennan 2011 Health centres Primary
health care
nurses
not stated not stated yes yes -
telephonic
yes - to hospi-
tal
Hospitals Doctors not stated not stated not applicable not applicable not applicable
Chan 2010 Health centres Nurses and
health surveil-
lance
assistants
no Expert
patients
yes yes - from hos-
pital
not stated
Hospitals Clinical
officers, nurses
and doctors
yes Home-
based care vol-
unteers
not applicable not applicable not stated
Fatti 2010 Health centres Doctors yes Commu-
nity-based ad-
herence coun-
sellors
not stated not stated not stated
Hospitals Doctors yes not stated not stated not stated not stated
Han-
sudewechakul
2012
health centres Nurses yes yes yes yes not stated
Hospital Doctors yes yes yes not applicable not stated
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Table 3. Description of the models of care of included studies (Continued)
Humphreys
2010
Health centres Nurses no not stated yes yes
- monthly visit
from nurse
and counsellor
yes
Hospital Doctors yes not stated not applicable not applicable not applicable
Full decentralisation
Assefa 2012 Health centres Health
officers, nurse
not stated Community
health work-
ers, adherence
counselling,
defaulter trac-
ing, refer-
ral and linkage
between facili-
ties
not stated not stated yes - to hospi-
tal
Hospitals Doctors not stated none not stated not stated not applicable
Balcha 2010 Health centres Health of-
ficers, nurses,
data clerk,
pharmacy
technicians
not stated not stated not stated not stated yes - to hospi-
tal
Hospitals Nurses, data
clerks,
pharmacists
not stated not stated not stated not stated not applicable
Bedelu 2007 Health centres Nurses no Community
health work-
ers, adherence
support, de-
faulter tracing
yes yes - mobile
team
yes - to hospi-
tal
Hospitals Doctors yes no not stated not applicable not applicable
Fayorsey 2013 health centres doctors and
nurses
8/
182 sites CD4
machines
variable by site not stated not stated yes
Hospitals doctors and
nurses
54/92 sites
Cd4 machines
variable by site not stated not stated not applicable
Massaquoi
2009
Health centres Medical assis-
tants and
nurse
yes yes yes yes yes - to hospi-
tal
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Table 3. Description of the models of care of included studies (Continued)
Hospitals Doctors yes not stated yes not applicable not applicable
McGuire
2012
Health centres Clinical
officers, nurses
and medical
assistants
yes yes yes not stated yes
Hospitals Clini-
cal officers and
nurses
yes yes not stated not stated not applicable
Odafe 2012 Hospitals Medical doc-
tors
yes yes not stated not stated not stated
Hospitals (ad-
vanced)
Medical spe-
cialists
yes not stated not stated not applicable not applicable
Decentralisation from facility to community
Jaffar Community Field officers no not stated yes yes yes
Health centres Clinical staff yes not stated yes yes not applicable
Kipp Community Unpaid
volunteers,
>18 years old
and literate
no Treatment
supporter to
assist with ad-
herence
yes yes yes
Health centres Doctors yes no not applicable not stated not applicable
Selke Community Commu-
nity care co-
ordinators
no Computer
aided devices
yes yes yes
Health centres Clinical offi-
cers, doctor (1
day/ week)
yes no not applicable not applicable not applicable
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A P P E N D I C E S
Appendix 1. Central search strategy
Database: CLIB Issue 4 of 12, April 2012 (1996 - 2012)
Date: 3 May 2012
ID Search
#1 MeSH descriptor HIV Infections explode all trees
#2 MeSH descriptor HIV explode all trees
#3 hiv OR hiv-1* OR hiv-2* OR hiv1 OR hiv2 OR HIV INFECT* OR HUMAN IMMUNODEFICIENCY VIRUS OR
HUMAN IMMUNEDEFICIENCY VIRUS OR HUMAN IMMUNE-DEFICIENCY VIRUS OR HUMAN
IMMUNO-DEFICIENCY VIRUS OR HUMAN IMMUN* DEFICIENCY VIRUS OR ACQUIRED
IMMUNODEFICIENCY SYNDROME OR ACQUIRED IMMUNEDEFICIENCY SYNDROME OR ACQUIRED
IMMUNO-DEFICIENCY SYNDROME OR ACQUIRED IMMUNE-DEFICIENCY SYNDROME OR ACQUIRED
IMMUN* DEFICIENCY SYNDROME
#4 MeSH descriptor Lymphoma, AIDS-Related, this term only
#5 MeSH descriptor Sexually Transmitted Diseases, Viral, this term only
#6 (#1 OR #2 OR #3 OR #4 OR #5)
#7 MeSH descriptor Antiretroviral Therapy, Highly Active, this term only
#8 MeSH descriptor Anti-HIV Agents explode all trees
#9 MeSH descriptor Antiviral Agents, this term only
#10 MeSH descriptor AIDS Vaccines, this term only
#11 ANTI HIV OR ANTIRETROVIRAL* OR ANTI RETROVIRAL* OR AIDS VACCIN*
#12 (#7 OR #8 OR #9 OR #10 OR #11)
#13 (#6 AND #12)
#14 MeSH descriptor Hospitals explode all trees
#15 (healthcare NEAR/6 (facility OR facilities OR centre OR centres OR center OR centers)):ti,ab
#16 (health NEAR/6 (facility OR facilities OR centre OR centres OR center OR centers)):ti,ab
#17 hospital:ti,ab OR hospitals:ti,ab OR clinic:ti,ab OR clinics:ti,ab
#18 home based:ti,ab OR facility based:ti,ab OR home care:ti,ab OR facility care:ti,ab
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(Continued)
#19 MeSH descriptor Health Facilities, this term only
#20 (#14 OR #15 OR #16 OR #17 OR #18 OR #19)
#21 MeSH descriptor Delivery of Health Care, this term only
#22 MeSH descriptor Health Services Accessibility, this term only
#23 MeSH descriptor Home Care Services, this term only
#24 (healthcare NEAR/6 (accessibility OR access OR system OR systems OR delivery)):ti,ab
#25 (health care NEAR/6 (accessibility OR access OR system OR systems OR delivery)):ti,ab
#26 (health services NEAR/6 (accessibility OR access OR system OR systems OR delivery)):ti,ab
#27 (#21 OR #22 OR #23 OR #24 OR #25 OR #26)
#28 (#13 AND #20 AND #27)
#29 (#13 AND #20 AND #27), from 1996 to 2012
Appendix 2. Medline search strategy
Database: PubMed (1996 - 2012
Date: 2 May 2012
Search Query
#7 Search #3 AND #4 AND #5 Limits: Publication Date from 1996/01/01 to 2012/05/02
#6 Search #3 AND #4 AND #5
#5 Search (health[tiab] OR healthcare[tiab] AND (facility[tiab] OR facilities[tiab] OR centre[tiab] OR centres[tiab] OR cen-
ter[tiab] OR centers[tiab])) OR hospital[tiab] OR hospitals[tiab] OR clinic[tiab] OR clinics[tiab] OR health facilities[mh]
OR home based[tiab] OR facility based[tiab] OR home care[tiab] OR facility care[tiab]
#4 Search (healthcare[tiab] OR health care[tiab] OR health services[tiab] AND (access[tiab] OR accessibility[tiab] OR sys-
tem[tiab] OR systems[tiab] OR delivery[tiab])) OR delivery of health care[mh:noexp] OR health services accessibility[mh:
noexp] OR decentrali*[tiab] OR referr*[tiab] OR home care services[mh:noexp]
#3 Search #1 AND #2
#2 Search Antiretroviral Therapy, Highly Active[MeSH] OR Anti-Retroviral Agents[MeSH] OR Antiviral Agents[MeSH:
NoExp] OR ((anti) AND (hiv[tw])) OR antiretroviral*[tw] OR ((anti) AND (retroviral*[tw])) ORHAART[tw] OR ((anti)
AND (acquired immunodeficiency[tw])) OR ((anti) AND (acquired immuno-deficiency[tw])) OR ((anti) AND (acquired
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(Continued)
immune-deficiency[tw])) OR ((anti) AND (acquired immun*) AND (deficiency[tw]))
#1 Search HIV Infections[MeSH] OR HIV[MeSH] OR hiv[tw] OR hiv-1*[tw] OR hiv-2*[tw] OR hiv1[tw] OR hiv2[tw]
OR hiv infect*[tw] OR human immunodeficiency virus[tw] OR human immunedeficiency virus[tw] OR human immuno-
deficiency virus[tw] OR human immune-deficiency virus[tw] OR ((human immun*) AND (deficiency virus[tw])) OR
acquired immunodeficiency syndrome[tw] OR acquired immunedeficiency syndrome[tw] OR acquired immuno-deficiency
syndrome[tw] OR acquired immune-deficiency syndrome[tw] OR ((acquired immun*) AND (deficiency syndrome[tw]))
Appendix 3. Embase search strategy
Database: EMBASE (1996 - 2012)
Date: 3 May 2012
No. Query
#16 #3 AND #8 AND #14 AND [humans]/lim AND [embase]/lim AND [1996-2012]/py
#15 #3 AND #8 AND #14
#14 #9 OR #10 OR #11 OR #12 OR #13
#13 ’home based’:ab,ti OR ’facility based’:ab,ti OR ’home care’/de OR ’home care’ OR ’facility care’:ab,ti
#12 hospital:ab,ti OR hospitals:ab,ti OR clinic:ab,ti OR clinics:ab,ti
#11 (health NEAR/6 (facility OR facilities OR centre OR centres OR center OR centers)):ab,ti
#10 (healthcare NEAR/6 (facility OR facilities OR centre OR centres OR center OR centers)):ab,ti
#9 ’health care facility’/exp OR ’health care facility’
#8 #4 OR #5 OR #6 OR #7
#7 ’health care delivery’/de OR decentrali*:ab,ti OR referr*:ab,ti
#6 (’health services’ NEAR/6 (delivery OR accessibility OR system OR systems OR access)):ab,ti
#5 (’health care’ NEAR/6 (delivery OR accessibility OR system OR systems OR access)):ab,ti
#4 (healthcare NEAR/6 (delivery OR accessibility OR system OR systems OR access)):ab,ti
#3 #1 AND #2
#2 ’human immunodeficiency virus vaccine’/de OR ’human immunodeficiency virus vaccine’ OR ’anti human immunedefi-
ciency’:ti OR ’anti human immunedeficiency’:ab OR ’anti human immunodeficiency’:ti OR ’anti human immunodeficiency’:
ab OR ’anti human immuno-deficiency’:ti OR ’anti human immuno-deficiency’:ab OR ’anti human immune-deficiency’:
69Decentralising HIV treatment in lower- and middle-income countries (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(Continued)
ti OR ’anti human immune-deficiency’:ab OR ’anti acquired immune-deficiency’:ti OR ’anti acquired immune-deficiency’:
ab OR ’anti acquired immunedeficiency’:ti OR ’anti acquired immunedeficiency’:ab OR ’anti acquired immunodeficiency’:
ti OR ’anti acquired immunodeficiency’:ab OR ’anti acquired immuno-deficiency’:ti OR ’anti acquired immuno-deficiency’:
ab OR ’anti hiv’:ti OR ’anti hiv’:ab OR antiretrovir*:ti OR antiretrovir*:ab OR ’anti retroviral’:ti OR ’anti retroviral’:ab OR
’anti retrovirals’:ti OR ’anti retrovirals’:ab OR ’anti retrovirus’:ti OR ’anti retrovirus’:ab OR haart:ti OR haart:ab OR ’aids
vaccine’:ti OR ’aids vaccine’:ab OR ’aids vaccines’:ti OR ’aids vaccines’:ab OR ’anti human immunodeficiency virus agent’/de
OR ’anti human immunodeficiency virus agent’ OR ’antiretrovirus agent’/de OR ’antiretrovirus agent’ OR ’antivirus agent’/
de OR ’antivirus agent’ OR ’highly active antiretroviral therapy’/de OR ’highly active antiretroviral therapy’
#1 ’human immunodeficiency virus infection’/exp OR ’human immunodeficiency virus infection’/de OR ’human immunod-
eficiency virus infection’ OR ’human immunodeficiency virus’/exp OR ’human immunodeficiency virus’/de OR ’human
immunodeficiency virus’ OR ’b cell lymphoma’/de OR ’b cell lymphoma’ OR hiv:ti OR hiv:ab OR ’hiv-1’:ti OR ’hiv-1’:ab
OR ’hiv-2’:ti OR ’hiv-2’:ab OR ’human immunodeficiency virus’:ti OR ’human immunodeficiency virus’:ab OR ’human
immunedeficiency virus’:ti OR ’human immunedeficiency virus’:ab OR ’human immune-deficiency virus’:ti OR ’human
immune-deficiency virus’:ab OR ’human immuno-deficiency virus’:ti OR ’human immuno-deficiency virus’:ab OR ’acquired
immunodeficiency syndrome’:ti OR ’acquired immunodeficiency syndrome’:abOR ’acquired immuno-deficiency syndrome’:
ti OR ’acquired immuno-deficiency syndrome’:ab OR ’acquired immune-deficiency syndrome’:ti OR ’acquired immune-
deficiency syndrome’:ab OR ’acquired immunedeficiency syndrome’:ti OR ’acquired immunedeficiency syndrome’:ab
Appendix 4. GRADE Evidence profile for partial decentralisation model
Question: Should antiretroviral therapy initiated in a hospital, maintained at a health centre be used in HIV infected patients?
Settings: Lower- and middle-income countries
Quality assessment No of patients Effect Qual-
ity
Im-
por-
tance
No of
stud-
ies
De-
sign
Risk
of bias
Incon-
sis-
tency
Indi-
rect-
ness
Im-
preci-
sion
Other
con-
sidera-
tions
An-
tiretro-
viral
ther-
apy
initi-
ated in
a hos-
pital,
main-
tained
at a
health
centre
Con-
trol
Rela-
tive
(95%
CI)
Abso-
lute
Death or lost to care (follow-up 12 months)
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(Continued)
4 obser-
va-
tional
studies
no seri-
ous
risk of
bias
no seri-
ous in-
consis-
tency1
no seri-
ous in-
direct-
ness2
no seri-
ous
impre-
cision
strong
associ-
ation3
3829/
23767
(16.
1%)
3337/
15323
(21.
8%)
RR 0.
46 (0.
29 to
0.71)
118
fewer
per
1000
(from
63
fewer
to 155
fewer)
⊕⊕⊕O
MOD-
ER-
ATE
CRIT-
ICAL
Lost to care (follow-up 12 months4)
4 obser-
va-
tional
studies
no seri-
ous
risk of
bias
no seri-
ous in-
consis-
tency5
no seri-
ous in-
direct-
ness2
no seri-
ous
impre-
cision
none 2229/
23767
(9.4%)
2055/
15323
(13.
4%)
RR 0.
55 (0.
45 to
0.69)
60
fewer
per
1000
(from
42
fewer
to 74
fewer)
⊕⊕OO
LOW
CRIT-
ICAL
Death (follow-up 12 months6)
4 obser-
va-
tional
studies
no seri-
ous
risk of
bias7
no seri-
ous in-
consis-
tency
7,8
no seri-
ous in-
direct-
ness2
no seri-
ous
impre-
cision
none9 1600/
23767
(6.7%)
1282/
15323
(8.4%)
RR 0.
34 (0.
13 to
0.87)
55
fewer
per
1000
(from
11
fewer
to 73
fewer)
⊕⊕OO
LOW
CRIT-
ICAL
1 No serious inconsistency. All four studies report a decrease in attrition at 12 months.
2 Not downgraded for indirectness. The studies included adults (two studies), children (1 study) or both (1 study); and were conducted
in sub-Saharan Africa (South Africa, Malawi).
3 Upgraded by 1 for large effect size. The effect estimate indicated a 54% decrease in attrition in the decentralised group.
4 Adjusted rates for Brennan 2011, Chan 2010 and Fatti 2010 are consistent with the crude proportions reported here. In Brennan
2011, the adjusted hazard ratio was 0.3 (95% CI 0.2 to 0.6)/ 100 person years indicating better outcomes at the health centre. Chan
2010 reported an adjusted odds ratio of 0.48 (95% CI 0.4 to 0.58) indicating better outcomes at the health centre. Fatti 2010 presented
the results inversing the site of risk, the adjusted hazard ratio was 2.19 (1.94 to 2.24) indicating greater problems with patients failing
to attend the hospital.
5 No serious inconsistency. Three of the four studies show benefit with varied effect sizes (39%. 51% and 66% reduction in patients
lost to care), the smallest study reports no difference in clinic follow-up at 12 months.
6 Adjusted rates for Brennan 2011, Chan 2010 and Fatti 2010 are consistent with the crude proportions reported here. In Brennan
2011, the adjusted hazard ratio was 0.2 (95% CI 0.04 to 0.8)/ 100 person years indicating better outcomes at the health centre.
Chan 2010 reported an adjusted odds ratio of 0.19 (95% CI 0.15 to 0.25) indicating better outcomes at the health centre. Fatti 2010
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presented the results inversing the site of risk, the adjusted hazard ratio was 1.6 (95% CI 1.3 to 1.99) indicating relatively increased
risk of death in patients attending the hospital.
7 Not downgraded for methodological limitations. For one included study (Fatti 2010), the health centre group had balanced CD4 cell
counts, but more severe illness - 79% had WHO clinical stage III or IV disease compared with 58% in the hospital group. However,
this would tend to favour the hospital group so we did not downgrade on baseline imbalance.
8 No serious inconsistency. All four studies show decrease in death at 12 months with varied effect sizes (10%, 74%, 77% and 81%
reductions).
9 Not upgraded for large effect size, despite large effect size and narrow confidence interval, this review is not aiming to explore
whether decentralisation decreases death, rather excluding that it increases death. The model of care down refers healthier patients for
maintenance therapy, generally sicker patients remain at the hospital setting, this therefore favours decentralisation.
Appendix 5. GRADE Evidence profile for full decentralisation model
Question: Should antiretroviral therapy be started and maintained in health centre be used in HIV infected patients?
Settings: Lower- and middle-income countries
Quality assessment No of patients Effect Qual-
ity
Im-
por-
tance
No of
stud-
ies
De-
sign
Risk
of bias
Incon-
sis-
tency
Indi-
rect-
ness
Im-
preci-
sion
Other
con-
sidera-
tions
An-
tiretro-
viral
ther-
apy be
started
and
main-
tained
in
health
centre
Con-
trol
Rela-
tive
(95%
CI)
Abso-
lute
Death or lost to care (follow-up 12 months)
4 obser-
va-
tional
studies
serious
1
no seri-
ous in-
consis-
tency2
no seri-
ous in-
direct-
ness3
serious
4
none 3895/
17753
(21.
9%)
14102/
38607
(36.
5%)
RR 0.
7 (0.47
to 1.
02)
110
fewer
per
1000
(from
194
fewer
to 7
more)
⊕OOO
VERY
LOW
CRIT-
ICAL
Lost to care (follow-up 12 months)
4 obser-
va-
tional
studies
no seri-
ous
risk of
bias5
no seri-
ous in-
consis-
tency6
no seri-
ous in-
direct-
ness3
no seri-
ous
impre-
cision
strong
associ-
ation7
2070/
17753
(11.
7%)
10429/
38607
(27%)
RR 0.
3 (0.17
to 0.
189
fewer
per
⊕⊕⊕O
CRIT-
ICAL
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(Continued)
54) 1000
(from
124
fewer
to 224
fewer)
MOD-
ER-
ATE
Death (follow-up 12 months)
4 obser-
va-
tional
studies
serious
1
serious
8
no seri-
ous in-
direct-
ness3
serious
9
none 1825/
17065
(10.
7%)
3673/
38034
(9.7%)
RR 1.
1 (0.63
to 1.
92)
10
more
per
1000
(from
36
fewer
to 89
more)
⊕OOO
VERY
LOW
CRIT-
ICAL
1 Downgraded by 1 for methodological limitations. Bedelu 2008, McGuire 2013 and Massaquoi 2009 included sicker patients at the
hospital setting, Assefa has unknown baseline risk as the CD4 counts and other baseline characteristics were not reported. This bias
would tend to favour therapy provided at the health centre.
2 Not downgraded for inconsistency. Three studies report significantly reduced attrition with decentralisation (13%, 42% and 52%),
while one study reported no difference.
3 Not downgraded for indirectness. The studies included adults (3 studies) or adults and children (1 study); and were conducted in
sub-Saharan Africa (South Africa, Malawi and Ethiopia). This model of care is probably applicable in better resourced settings where
basic levels of healthcare are likely to be better resourced, favouring decentralisation.
4 Downgraded by 1 for imprecision. Although the sample sizes are large and event rates are high, the confidence interval is wide
including both appreciable benefit and the null effect.
5 Not downgraded for risk of bias. Four retrospective cohorts provided data. Although there were differences in their baseline health
status (Bedelu 2008, Massaquoi 2009 and McGuire 2012 included sicker patients at the hospital), this study limitation is not expected
to impact on the attendance at the clinic.
6 Not downgraded for inconsistency. All four studies showed substantially better clinic attendance with decentralisation, however, the
effect sizes varied, 24%, 63%, 80% and 89% reductions.
7 Upgraded by 1 for large effect size . The effect size indicates a 70% lower rate of failure to attend clinic follow-up at the health center
compared to hospital.
8 Downgraded for inconsistency.There is qualitative heterogeneity, Bedelu 2008, Massaquoi 2009 and McGuire 2013 include sicker
patients at the hospital, yet only McGuire showed increased death in that setting. Therefore the inconsistency is unexplained.
9 Downgraded by 1 for imprecision. Although the sample sizes are large and event rates are high, the confidence interval is wide
including both appreciable benefit and harm.
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Appendix 6. GRADE evidence profile community model of care
Question: Should decentralisation from the facility to the community for antiretroviral maintenance therapy be used in HIV-infected
patients on antiretroviral therapy?
Settings: Lower- and middle-income countries
Quality assessment No of patients Effect Qual-
ity
Im-
por-
tance
No of
stud-
ies
De-
sign
Risk
of bias
Incon-
sis-
tency
Indi-
rect-
ness
Im-
preci-
sion
Other
con-
sidera-
tions
De-
cen-
trali-
sation
from
the fa-
cility
to the
com-
mu-
nity
for an-
tiretro-
viral
main-
te-
nance
ther-
apy
Con-
trol
Rela-
tive
(95%
CI)
Abso-
lute
Death or lost to care (follow-up 12 months)
2 ran-
domised
trials
no seri-
ous
risk of
bias
no seri-
ous in-
consis-
tency
no seri-
ous in-
direct-
ness1
serious
2
none 43/
399
(10.
8%)
33/
310
(10.
6%)
RR 0.
95 (0.
62 to
1.46)
5 fewer
per
1000
(from
40
fewer
to 49
more)
⊕⊕⊕O
MOD-
ER-
ATE
CRIT-
ICAL
Lost to care (follow-up 12 months3)
2 ran-
domised
trials
no seri-
ous
risk of
bias
no seri-
ous in-
consis-
tency
no seri-
ous in-
direct-
ness1
serious
2
none 7/399
(1.8%)
8/310
(2.6%)
RR 0.
81 (0.
3 to 2.
21)
5 fewer
per
1000
(from
18
fewer
to 31
more)
⊕⊕⊕O
MOD-
ER-
ATE
CRIT-
ICAL
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(Continued)
Death (follow-up 12 months4)
2 ran-
domised
trials
no seri-
ous
risk of
bias
no seri-
ous in-
consis-
tency
no seri-
ous in-
direct-
ness1
serious
2
none 37/
399
(9.3%)
5.5% RR 1.
03 (0.
64 to
1.65)
2 more
per
1000
(from
20
fewer
to 36
more)
⊕⊕⊕O
MOD-
ER-
ATE
CRIT-
ICAL
1 Not downgraded for indirectness. Note that the trials were conducted in Kenya and Uganda in adult populations.
2 Downgraded by 1 for imprecision. These two cluster trials have been pooled after adjusting for the design effect. The intra-cluster
co-efficient was assumed, as it was not provided in the trial reports.The included studies have small sample sizes and wide confidence
intervals which include appreciable harm and benefit.
3 The cluster randomised controlled trials Selke 2010 and Jaffar 2009 are included in this pooled analysis. Selke 2010 reports the
adjusted incidence rate ratio for patients lost to care as IRR 1.15 (95% CI 0.24 to 3.03), P = 1.0
4 The cluster randomised controlled trials Selke 2010 and Jaffar 2009 are included in this pooled analysis. Jaffar 2009 reports the
adjusted rate ratio for death, RR 0.95(95% CI 0.71 to 1.28); Selke 2010 did not provide adjusted rates for this outcome.
H I S T O R Y
Protocol first published: Issue 7, 2012
Review first published: Issue 6, 2013
Date Event Description
8 June 2012 Amended New author, FBA added to team
13 March 2009 Amended Converted to new review format.
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